ID ATR_HUMAN Reviewed; 2644 AA. AC Q13535; Q59HB2; Q7KYL3; Q93051; Q9BXK4; DT 29-MAR-2005, integrated into UniProtKB/Swiss-Prot. DT 05-JUL-2004, sequence version 3. DT 28-JAN-2026, entry version 219. DE RecName: Full=Serine/threonine-protein kinase ATR; DE EC=2.7.11.1 {ECO:0000269|PubMed:21705319, ECO:0000269|PubMed:21777809, ECO:0000269|PubMed:27723717, ECO:0000269|PubMed:27723720}; DE AltName: Full=Ataxia telangiectasia and Rad3-related protein; DE AltName: Full=FRAP-related protein 1; GN Name=ATR {ECO:0000303|PubMed:14729973, ECO:0000312|HGNC:HGNC:882}; GN Synonyms=FRP1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8978690; DOI=10.1002/j.1460-2075.1996.tb01054.x; RA Bentley N.J., Holtzman D.A., Flaggs G., Keegan K.S., DeMaggio A., RA Ford J.C., Hoekstra M., Carr A.M.; RT "The Schizosaccharomyces pombe rad3 checkpoint gene."; RL EMBO J. 15:6641-6651(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY. RC TISSUE=T-cell; RX PubMed=8610130; DOI=10.1073/pnas.93.7.2850; RA Cimprich K.A., Shin T.B., Keith C.T., Schreiber S.L.; RT "cDNA cloning and gene mapping of a candidate human cell cycle checkpoint RT protein."; RL Proc. Natl. Acad. Sci. U.S.A. 93:2850-2855(1996). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 433-526 (ISOFORMS 1 AND 2), AND RP TISSUE SPECIFICITY. RX PubMed=11470508; DOI=10.1016/s0378-1119(01)00543-1; RA Mannino J.L., Kim W.-J., Wernick M., Nguyen S.V., Braquet R., Adamson A.W., RA Den Z., Batzer M.A., Collins C.C., Brown K.D.; RT "Evidence for alternate splicing within the mRNA transcript encoding the RT DNA damage response kinase ATR."; RL Gene 272:35-43(2001). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2155-2644 (ISOFORM 3). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=8843195; DOI=10.1101/gad.10.19.2423; RA Keegan K.S., Holtzman D.A., Plug A.W., Christenson E.R., Brainerd E.E., RA Flaggs G., Bentley N.J., Taylor E.M., Meyn M.S., Moss S.B., Carr A.M., RA Ashley T., Hoekstra M.F.; RT "The Atr and Atm protein kinases associate with different sites along RT meiotically pairing chromosomes."; RL Genes Dev. 10:2423-2437(1996). RN [6] RP ACTIVITY REGULATION. RX PubMed=9766667; RA Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.E., RA Abraham R.T.; RT "Inhibition of phosphoinositide 3-kinase related kinases by the RT radiosensitizing agent wortmannin."; RL Cancer Res. 58:4375-4382(1998). RN [7] RP FUNCTION, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF ASP-2475. RX PubMed=9427750; DOI=10.1093/emboj/17.1.159; RA Cliby W.A., Roberts C.J., Cimprich K.A., Stringer C.M., Lamb J.R., RA Schreiber S.L., Friend S.H.; RT "Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA- RT damaging agents and defects in cell cycle checkpoints."; RL EMBO J. 17:159-169(1998). RN [8] RP FUNCTION, AND MUTAGENESIS OF ASP-2494. RX PubMed=9636169; DOI=10.1073/pnas.95.13.7445; RA Wright J.A., Keegan K.S., Herendeen D.R., Bentley N.J., Carr A.M., RA Hoekstra M.F., Concannon P.; RT "Protein kinase mutants of human ATR increase sensitivity to UV and RT ionizing radiation and abrogate cell cycle checkpoint control."; RL Proc. Natl. Acad. Sci. U.S.A. 95:7445-7450(1998). RN [9] RP INTERACTION WITH HDAC2, AND IDENTIFICATION IN A COMPLEX CONTAINING HDAC2 RP AND CHD4. RX PubMed=10545197; DOI=10.1021/bi991614n; RA Schmidt D.R., Schreiber S.L.; RT "Molecular association between ATR and two components of the nucleosome RT remodeling and deacetylating complex, HDAC2 and CHD4."; RL Biochemistry 38:14711-14717(1999). RN [10] RP FUNCTION, AND MUTAGENESIS OF LYS-2327 AND ASP-2475. RX PubMed=9925639; DOI=10.1101/gad.13.2.152; RA Tibbetts R.S., Brumbaugh K.M., Williams J.M., Sarkaria J.N., Cliby W.A., RA Shieh S.-Y., Taya Y., Prives C., Abraham R.T.; RT "A role for ATR in the DNA damage-induced phosphorylation of p53."; RL Genes Dev. 13:152-157(1999). RN [11] RP COFACTOR, AND FUNCTION. RX PubMed=10608806; DOI=10.1074/jbc.274.53.37538; RA Kim S.-T., Lim D.-S., Canman C.E., Kastan M.B.; RT "Substrate specificities and identification of putative substrates of ATM RT kinase family members."; RL J. Biol. Chem. 274:37538-37543(1999). RN [12] RP FUNCTION, AUTOPHOSPHORYLATION, MUTAGENESIS OF ASP-2494, AND ACTIVITY RP REGULATION. RX PubMed=10597277; DOI=10.1038/sj.onc.1203077; RA Hall-Jackson C.A., Cross D.A.E., Morrice N., Smythe C.; RT "ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate RT specificity distinct from DNA-PK."; RL Oncogene 18:6707-6713(1999). RN [13] RP FUNCTION. RX PubMed=10859164; RA Liu Q., Guntuku S., Cui X.-S., Matsuoka S., Cortez D., Tamai K., Luo G., RA Carattini-Rivera S., DeMayo F., Bradley A., Donehower L.A., Elledge S.J.; RT "Chk1 is an essential kinase that is regulated by Atr and required for the RT G(2)/M DNA damage checkpoint."; RL Genes Dev. 14:1448-1459(2000). RN [14] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-2327. RX PubMed=11114888; DOI=10.1101/gad.851000; RA Tibbetts R.S., Cortez D., Brumbaugh K.M., Scully R., Livingston D., RA Elledge S.J., Abraham R.T.; RT "Functional interactions between BRCA1 and the checkpoint kinase ATR during RT genotoxic stress."; RL Genes Dev. 14:2989-3002(2000). RN [15] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=11673449; DOI=10.1074/jbc.c100569200; RA Ward I.M., Chen J.; RT "Histone H2AX is phosphorylated in an ATR-dependent manner in response to RT replicational stress."; RL J. Biol. Chem. 276:47759-47762(2001). RN [16] RP FUNCTION. RX PubMed=11418864; DOI=10.1038/35082110; RA Bao S., Tibbetts R.S., Brumbaugh K.M., Fang Y., Richardson D.A., Ali A., RA Chen S.M., Abraham R.T., Wang X.-F.; RT "ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic RT stress responses."; RL Nature 411:969-974(2001). RN [17] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH ATRIP. RX PubMed=11721054; DOI=10.1126/science.1065521; RA Cortez D., Guntuku S., Qin J., Elledge S.J.; RT "ATR and ATRIP: partners in checkpoint signaling."; RL Science 294:1713-1716(2001). RN [18] RP FUNCTION. RX PubMed=12526805; DOI=10.1016/s0092-8674(02)01113-3; RA Casper A.M., Nghiem P., Arlt M.F., Glover T.W.; RT "ATR regulates fragile site stability."; RL Cell 111:779-789(2002). RN [19] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=11865061; DOI=10.1128/mcb.22.6.1834-1843.2002; RA Hammond E.M., Denko N.C., Dorie M.J., Abraham R.T., Giaccia A.J.; RT "Hypoxia links ATR and p53 through replication arrest."; RL Mol. Cell. Biol. 22:1834-1843(2002). RN [20] RP DNA-BINDING, AND MUTAGENESIS OF LYS-2327. RX PubMed=12011431; DOI=10.1073/pnas.102167799; RA Uensal-Kacmaz K., Makhov A.M., Griffith J.D., Sancar A.; RT "Preferential binding of ATR protein to UV-damaged DNA."; RL Proc. Natl. Acad. Sci. U.S.A. 99:6673-6678(2002). RN [21] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASP-2475. RX PubMed=12814551; DOI=10.1016/s0960-9822(03)00376-2; RA Barr S.M., Leung C.G., Chang E.E., Cimprich K.A.; RT "ATR kinase activity regulates the intranuclear translocation of ATR and RT RPA following ionizing radiation."; RL Curr. Biol. 13:1047-1051(2003). RN [22] RP INTERACTION WITH CLSPN. RX PubMed=12766152; DOI=10.1074/jbc.m301136200; RA Chini C.C.S., Chen J.; RT "Human claspin is required for replication checkpoint control."; RL J. Biol. Chem. 278:30057-30062(2003). RN [23] RP FUNCTION, INTERACTION WITH MSH2, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=14657349; DOI=10.1073/pnas.2536810100; RA Wang Y., Qin J.; RT "MSH2 and ATR form a signaling module and regulate two branches of the RT damage response to DNA methylation."; RL Proc. Natl. Acad. Sci. U.S.A. 100:15387-15392(2003). RN [24] RP FUNCTION, DNA-BINDING, AND IDENTIFICATION IN A COMPLEX WITH RPA AND ATRIP. RX PubMed=12791985; DOI=10.1126/science.1083430; RA Zou L., Elledge S.J.; RT "Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes."; RL Science 300:1542-1548(2003). RN [25] RP INTERACTION WITH BCR-ABL. RX PubMed=15050919; DOI=10.1016/s1535-6108(04)00056-x; RA Dierov J., Dierova R., Carroll M.; RT "BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S RT phase checkpoint."; RL Cancer Cell 5:275-285(2004). RN [26] RP FUNCTION. RX PubMed=14742437; DOI=10.1074/jbc.c300554200; RA Ward I.M., Minn K., Chen J.; RT "UV-induced ataxia-telangiectasia-mutated and Rad3-related (ATR) activation RT requires replication stress."; RL J. Biol. Chem. 279:9677-9680(2004). RN [27] RP DNA-BINDING, AND SUBCELLULAR LOCATION. RX PubMed=14871897; DOI=10.1074/jbc.m314212200; RA Dart D.A., Adams K.E., Akerman I., Lakin N.D.; RT "Recruitment of the cell cycle checkpoint kinase ATR to chromatin during S- RT phase."; RL J. Biol. Chem. 279:16433-16440(2004). RN [28] RP FUNCTION. RX PubMed=15314022; DOI=10.1101/gad.1196104; RA Andreassen P.R., D'Andrea A.D., Taniguchi T.; RT "ATR couples FANCD2 monoubiquitination to the DNA-damage response."; RL Genes Dev. 18:1958-1963(2004). RN [29] RP FUNCTION. RX PubMed=15496423; DOI=10.1093/hmg/ddh335; RA Alderton G.K., Joenje H., Varon R., Borglum A.D., Jeggo P.A., RA O'Driscoll M.; RT "Seckel syndrome exhibits cellular features demonstrating defects in the RT ATR-signalling pathway."; RL Hum. Mol. Genet. 13:3127-3138(2004). RN [30] RP FUNCTION, SUBUNIT, IDENTIFICATION IN A COMPLEX WITH ATRIP AND RPA1, RP DNA-BINDING, AND ACTIVITY REGULATION. RX PubMed=14729973; DOI=10.1128/mcb.24.3.1292-1300.2003; RA Uensal-Kacmaz K., Sancar A.; RT "Quaternary structure of ATR and effects of ATRIP and replication protein A RT on its DNA binding and kinase activities."; RL Mol. Cell. Biol. 24:1292-1300(2004). RN [31] RP FUNCTION. RX PubMed=15210935; DOI=10.1073/pnas.0403410101; RA Cortez D., Glick G., Elledge S.J.; RT "Minichromosome maintenance proteins are direct targets of the ATM and ATR RT checkpoint kinases."; RL Proc. Natl. Acad. Sci. U.S.A. 101:10078-10083(2004). RN [32] RP INTERACTION WITH EEF1E1. RX PubMed=15680327; DOI=10.1016/j.cell.2004.11.054; RA Park B.-J., Kang J.W., Lee S.W., Choi S.-J., Shin Y.K., Ahn Y.H., RA Choi Y.H., Choi D., Lee K.S., Kim S.; RT "The haploinsufficient tumor suppressor p18 upregulates p53 via RT interactions with ATM/ATR."; RL Cell 120:209-221(2005). RN [33] RP INTERACTION WITH ATRIP. RX PubMed=15758953; DOI=10.1038/nature03442; RA Falck J., Coates J., Jackson S.P.; RT "Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA RT damage."; RL Nature 434:605-611(2005). RN [34] RP ACTIVITY REGULATION. RX PubMed=16530042; DOI=10.1016/j.cell.2005.12.041; RA Kumagai A., Lee J., Yoo H.Y., Dunphy W.G.; RT "TopBP1 activates the ATR-ATRIP complex."; RL Cell 124:943-955(2006). RN [35] RP INTERACTION WITH CEP164, AND SUBCELLULAR LOCATION. RX PubMed=18283122; DOI=10.1101/gad.1627708; RA Sivasubramaniam S., Sun X., Pan Y.R., Wang S., Lee E.Y.; RT "Cep164 is a mediator protein required for the maintenance of genomic RT stability through modulation of MDC1, RPA, and CHK1."; RL Genes Dev. 22:587-600(2008). RN [36] RP INVOLVEMENT IN SCKL1. RX PubMed=12640452; DOI=10.1038/ng1129; RA O'Driscoll M., Ruiz-Perez V.L., Woods C.G., Jeggo P.A., Goodship J.A.; RT "A splicing mutation affecting expression of ataxia-telangiectasia and RT Rad3-related protein (ATR) results in Seckel syndrome."; RL Nat. Genet. 33:497-501(2003). RN [37] RP FUNCTION IN DNA DAMAGE RESPONSE, AUTOPHOSPHORYLATION, AND SUBCELLULAR RP LOCATION. RX PubMed=16260606; DOI=10.1128/mcb.25.22.9910-9919.2005; RA Zhang J., Bao S., Furumai R., Kucera K.S., Ali A., Dean N.M., Wang X.F.; RT "Protein phosphatase 5 is required for ATR-mediated checkpoint RT activation."; RL Mol. Cell. Biol. 25:9910-9919(2005). RN [38] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-428 AND THR-1989, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [39] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [40] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [41] RP INTERACTION WITH TTI1. RX PubMed=20810650; DOI=10.1101/gad.1934210; RA Hurov K.E., Cotta-Ramusino C., Elledge S.J.; RT "A genetic screen identifies the Triple T complex required for DNA damage RT signaling and ATM and ATR stability."; RL Genes Dev. 24:1939-1950(2010). RN [42] RP INTERACTION WITH TELO2. RX PubMed=20801936; DOI=10.1101/gad.1956410; RA Takai H., Xie Y., de Lange T., Pavletich N.P.; RT "Tel2 structure and function in the Hsp90-dependent maturation of mTOR and RT ATR complexes."; RL Genes Dev. 24:2019-2030(2010). RN [43] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [44] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [45] RP FUNCTION IN DNA REPAIR, AND PHOSPHORYLATION AT SER-428. RX PubMed=21144835; DOI=10.1016/j.bbrc.2010.12.005; RA Kang Y., Cheong H.M., Lee J.H., Song P.I., Lee K.H., Kim S.Y., Jun J.Y., RA You H.J.; RT "Protein phosphatase 5 is necessary for ATR-mediated DNA repair."; RL Biochem. Biophys. Res. Commun. 404:476-481(2011). RN [46] RP PHOSPHORYLATION AT THR-1989, AND MUTAGENESIS OF THR-1989. RX PubMed=21705319; DOI=10.1074/jbc.m111.248914; RA Nam E.A., Zhao R., Glick G.G., Bansbach C.E., Friedman D.B., Cortez D.; RT "Thr-1989 phosphorylation is a marker of active ataxia telangiectasia- RT mutated and Rad3-related (ATR) kinase."; RL J. Biol. Chem. 286:28707-28714(2011). RN [47] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-428; SER-435 AND RP THR-1989, ACTIVITY REGULATION, AND INTERACTION WITH ATRIP AND TOPBP1. RX PubMed=21777809; DOI=10.1016/j.molcel.2011.06.019; RA Liu S., Shiotani B., Lahiri M., Marechal A., Tse A., Leung C.C., RA Glover J.N., Yang X.H., Zou L.; RT "ATR autophosphorylation as a molecular switch for checkpoint activation."; RL Mol. Cell 43:192-202(2011). RN [48] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-435; SER-436 AND THR-1989, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [50] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=23273981; DOI=10.1016/j.molcel.2012.11.020; RA Peterson S.E., Li Y., Wu-Baer F., Chait B.T., Baer R., Yan H., RA Gottesman M.E., Gautier J.; RT "Activation of DSB processing requires phosphorylation of CtIP by ATR."; RL Mol. Cell 49:657-667(2013). RN [51] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=25083873; DOI=10.1016/j.cell.2014.05.046; RA Kumar A., Mazzanti M., Mistrik M., Kosar M., Beznoussenko G.V., RA Mironov A.A., Garre M., Parazzoli D., Shivashankar G.V., Scita G., RA Bartek J., Foiani M.; RT "ATR mediates a checkpoint at the nuclear envelope in response to RT mechanical stress."; RL Cell 158:633-646(2014). RN [52] RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND ACTIVITY RP REGULATION. RX PubMed=27723720; DOI=10.1038/ncb3415; RA Bass T.E., Luzwick J.W., Kavanaugh G., Carroll C., Dungrawala H., RA Glick G.G., Feldkamp M.D., Putney R., Chazin W.J., Cortez D.; RT "ETAA1 acts at stalled replication forks to maintain genome integrity."; RL Nat. Cell Biol. 18:1185-1195(2016). RN [53] RP FUNCTION, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION. RX PubMed=27723717; DOI=10.1038/ncb3422; RA Haahr P., Hoffmann S., Tollenaere M.A., Ho T., Toledo L.I., Mann M., RA Bekker-Jensen S., Raeschle M., Mailand N.; RT "Activation of the ATR kinase by the RPA-binding protein ETAA1."; RL Nat. Cell Biol. 18:1196-1207(2016). RN [54] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=30139873; DOI=10.1126/science.aap9346; RA Saldivar J.C., Hamperl S., Bocek M.J., Chung M., Bass T.E., RA Cisneros-Soberanis F., Samejima K., Xie L., Paulson J.R., Earnshaw W.C., RA Cortez D., Meyer T., Cimprich K.A.; RT "An intrinsic S/G2 checkpoint enforced by ATR."; RL Science 361:806-810(2018). RN [55] RP FUNCTION, AND INTERACTION WITH UHRF2. RX PubMed=33848395; DOI=10.1111/gtc.12851; RA Hanaki S., Habara M., Shimada M.; RT "UV-induced activation of ATR is mediated by UHRF2."; RL Genes Cells 26:447-454(2021). RN [56] RP FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION. RX PubMed=37788673; DOI=10.1016/j.molcel.2023.09.003; RA Joo Y.K., Black E.M., Trier I., Haakma W., Zou L., Kabeche L.; RT "ATR promotes clearance of damaged DNA and damaged cells by rupturing RT micronuclei."; RL Mol. Cell 83:3642-3658(2023). RN [57] RP FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION. RX PubMed=37832547; DOI=10.1016/j.molcel.2023.09.023; RA Kovacs M.T., Vallette M., Wiertsema P., Dingli F., Loew D., Nader G.P.F., RA Piel M., Ceccaldi R.; RT "DNA damage induces nuclear envelope rupture through ATR-mediated RT phosphorylation of lamin A/C."; RL Mol. Cell 83:3659-3668(2023). RN [58] RP VARIANTS [LARGE SCALE ANALYSIS] ALA-64; TYR-90; ASN-297; ILE-316; MET-959; RP HIS-1087; GLY-1213; PRO-1488; ASN-1607; SER-1612; GLY-2002; ALA-2120; RP ASP-2132; ILE-2233; GLN-2425; ALA-2434; LYS-2438 AND GLN-2537. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [59] RP VARIANT FCTCS ARG-2144. RX PubMed=22341969; DOI=10.1016/j.ajhg.2012.01.007; RA Tanaka A., Weinel S., Nagy N., O'Driscoll M., Lai-Cheong J.E., RA Kulp-Shorten C.L., Knable A., Carpenter G., Fisher S.A., Hiragun M., RA Yanase Y., Hide M., Callen J., McGrath J.A.; RT "Germline mutation in ATR in autosomal- dominant oropharyngeal cancer RT syndrome."; RL Am. J. Hum. Genet. 90:511-517(2012). CC -!- FUNCTION: Serine/threonine protein kinase which activates checkpoint CC signaling upon genotoxic stresses such as ionizing radiation (IR), CC ultraviolet light (UV), or DNA replication stalling, thereby acting as CC a DNA damage sensor (PubMed:10597277, PubMed:10608806, PubMed:10859164, CC PubMed:11721054, PubMed:12791985, PubMed:12814551, PubMed:14657349, CC PubMed:14729973, PubMed:14742437, PubMed:15210935, PubMed:15496423, CC PubMed:16260606, PubMed:21144835, PubMed:21777809, PubMed:23273981, CC PubMed:25083873, PubMed:27723717, PubMed:27723720, PubMed:30139873, CC PubMed:33848395, PubMed:37788673, PubMed:37832547, PubMed:9427750, CC PubMed:9636169). Recognizes the substrate consensus sequence [ST]-Q CC (PubMed:10597277, PubMed:10608806, PubMed:10859164, PubMed:11721054, CC PubMed:12791985, PubMed:12814551, PubMed:14657349, PubMed:14729973, CC PubMed:14742437, PubMed:15210935, PubMed:15496423, PubMed:16260606, CC PubMed:21144835, PubMed:23273981, PubMed:27723717, PubMed:27723720, CC PubMed:33848395, PubMed:9427750, PubMed:9636169). Phosphorylates BRCA1, CC CHEK1, MCM2, RAD17, RBBP8, RPA2, SMC1 and p53/TP53, which collectively CC inhibit DNA replication and mitosis and promote DNA repair, CC recombination and apoptosis (PubMed:11114888, PubMed:11418864, CC PubMed:11865061, PubMed:21777809, PubMed:23273981, PubMed:25083873, CC PubMed:9925639). Phosphorylates 'Ser-139' of histone variant H2AX at CC sites of DNA damage, thereby regulating DNA damage response mechanism CC (PubMed:11673449). Required for FANCD2 ubiquitination CC (PubMed:15314022). Critical for maintenance of fragile site stability CC and efficient regulation of centrosome duplication (PubMed:12526805). CC Acts as a regulator of the S-G2 transition by restricting the activity CC of CDK1 during S-phase to prevent premature entry into G2 CC (PubMed:30139873). Acts as a regulator of the nuclear envelope CC integrity in response to DNA damage and stress (PubMed:25083873, CC PubMed:37788673, PubMed:37832547). Acts as a mechanical stress sensor CC at the nuclear envelope: relocalizes to the nuclear envelope in CC response to mechanical stress and mediates a checkpoint via CC phosphorylation of CHEK1 (PubMed:25083873). Also promotes nuclear CC envelope rupture in response to DNA damage by mediating phosphorylation CC of LMNA at 'Ser-282', leading to lamin disassembly (PubMed:37832547). CC Involved in the inflammatory response to genome instability and double- CC stranded DNA breaks: acts by localizing to micronuclei arising from CC genome instability and catalyzing phosphorylation of LMNA at 'Ser-395', CC priming LMNA for subsequent phosphorylation by CDK1 and micronuclei CC envelope rupture (PubMed:37788673). The rupture of micronuclear CC envelope triggers the cGAS-STING pathway thereby activating the type I CC interferon response and innate immunity (PubMed:37788673). Positively CC regulates the restart of stalled replication forks following activation CC by the KHDC3L-OOEP scaffold complex (By similarity). CC {ECO:0000250|UniProtKB:Q9JKK8, ECO:0000269|PubMed:10597277, CC ECO:0000269|PubMed:10608806, ECO:0000269|PubMed:10859164, CC ECO:0000269|PubMed:11114888, ECO:0000269|PubMed:11418864, CC ECO:0000269|PubMed:11673449, ECO:0000269|PubMed:11721054, CC ECO:0000269|PubMed:11865061, ECO:0000269|PubMed:12526805, CC ECO:0000269|PubMed:12791985, ECO:0000269|PubMed:12814551, CC ECO:0000269|PubMed:14657349, ECO:0000269|PubMed:14729973, CC ECO:0000269|PubMed:14742437, ECO:0000269|PubMed:15210935, CC ECO:0000269|PubMed:15314022, ECO:0000269|PubMed:15496423, CC ECO:0000269|PubMed:16260606, ECO:0000269|PubMed:21144835, CC ECO:0000269|PubMed:21777809, ECO:0000269|PubMed:23273981, CC ECO:0000269|PubMed:25083873, ECO:0000269|PubMed:27723717, CC ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:30139873, CC ECO:0000269|PubMed:33848395, ECO:0000269|PubMed:37788673, CC ECO:0000269|PubMed:37832547, ECO:0000269|PubMed:9427750, CC ECO:0000269|PubMed:9636169, ECO:0000269|PubMed:9925639}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:23273981, ECO:0000269|PubMed:27723717, CC ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:37788673, CC ECO:0000269|PubMed:37832547}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:23273981, ECO:0000269|PubMed:27723717, CC ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:37788673, CC ECO:0000269|PubMed:37832547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21705319, ECO:0000269|PubMed:21777809, CC ECO:0000269|PubMed:27723717, ECO:0000269|PubMed:27723720}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:21705319, ECO:0000269|PubMed:21777809, CC ECO:0000269|PubMed:27723717, ECO:0000269|PubMed:27723720}; CC -!- COFACTOR: CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC Evidence={ECO:0000269|PubMed:10608806}; CC -!- ACTIVITY REGULATION: Serine/threonine-protein kinase activity is CC directly stimulated by TOPBP1 (PubMed:16530042, PubMed:21777809). ATR CC kinase activity is also directly activated by ETAA1, independently of CC TOPBP1 (PubMed:27723717, PubMed:27723720, PubMed:30139873). Activated CC by DNA and inhibited by BCR-ABL oncogene (PubMed:10597277). Slightly CC activated by ATRIP (PubMed:14729973). Inhibited by caffeine, wortmannin CC and LY294002 (PubMed:9766667). {ECO:0000269|PubMed:10597277, CC ECO:0000269|PubMed:14729973, ECO:0000269|PubMed:16530042, CC ECO:0000269|PubMed:21777809, ECO:0000269|PubMed:27723717, CC ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:30139873, CC ECO:0000269|PubMed:9766667}. CC -!- SUBUNIT: Forms a heterodimer with ATRIP, forming the ATR-ATRIP complex CC (PubMed:11721054, PubMed:12791985, PubMed:14729973, PubMed:15758953, CC PubMed:21777809). Present in a complex containing ATRIP and RPA-coated CC single-stranded DNA (PubMed:12791985, PubMed:14729973). Binds to DNA, CC and to UV-damaged DNA with higher affinity (PubMed:12791985). Interacts CC with MSH2 and HDAC2 (PubMed:14657349). Present in a complex containing CC CHD4 and HDAC2 (PubMed:10545197). Interacts with EEF1E1, the CC interaction is enhanced by UV irradiation (PubMed:15680327). Interacts CC with CLSPN and CEP164 (PubMed:12766152, PubMed:18283122). Interacts CC with TELO2 and TTI1 (PubMed:20427287, PubMed:20801936, CC PubMed:20810650). Interacts with BCR-ABL after genotoxic stress CC (PubMed:15050919). Interacts with UHRF2; this interaction promotes ATR CC activation (PubMed:33848395). Interacts (when phosphorylated) with CC TOPBP1; interaction takes place when ATR is autophosphorylated at Thr- CC 1989, leading to ATR activation by TOPBP1 (PubMed:21705319, CC PubMed:21777809). {ECO:0000269|PubMed:10545197, CC ECO:0000269|PubMed:11721054, ECO:0000269|PubMed:12766152, CC ECO:0000269|PubMed:12791985, ECO:0000269|PubMed:14657349, CC ECO:0000269|PubMed:14729973, ECO:0000269|PubMed:15050919, CC ECO:0000269|PubMed:15680327, ECO:0000269|PubMed:15758953, CC ECO:0000269|PubMed:18283122, ECO:0000269|PubMed:20427287, CC ECO:0000269|PubMed:20801936, ECO:0000269|PubMed:20810650, CC ECO:0000269|PubMed:21705319, ECO:0000269|PubMed:21777809, CC ECO:0000269|PubMed:33848395}. CC -!- INTERACTION: CC Q13535; Q8WXE1: ATRIP; NbExp=5; IntAct=EBI-968983, EBI-747353; CC Q13535; Q99459: CDC5L; NbExp=3; IntAct=EBI-968983, EBI-374880; CC Q13535; P50750: CDK9; NbExp=3; IntAct=EBI-968983, EBI-1383449; CC Q13535; Q9BW66: CINP; NbExp=5; IntAct=EBI-968983, EBI-739784; CC Q13535; Q9Y6K9: IKBKG; NbExp=2; IntAct=EBI-968983, EBI-81279; CC Q13535; O43156: TTI1; NbExp=2; IntAct=EBI-968983, EBI-1055680; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11114888, CC ECO:0000269|PubMed:11721054, ECO:0000269|PubMed:11865061, CC ECO:0000269|PubMed:12814551, ECO:0000269|PubMed:14871897, CC ECO:0000269|PubMed:16260606, ECO:0000269|PubMed:18283122, CC ECO:0000269|PubMed:27723720, ECO:0000269|PubMed:8843195}. Chromosome CC {ECO:0000269|PubMed:11673449}. Nucleus envelope CC {ECO:0000269|PubMed:25083873, ECO:0000269|PubMed:37788673, CC ECO:0000269|PubMed:37832547}. Note=Depending on the cell type, it can CC also be found in PML nuclear bodies (PubMed:12814551). Recruited to CC chromatin during S-phase (PubMed:14871897). Redistributes to discrete CC nuclear foci upon DNA damage, hypoxia or replication fork stalling CC (PubMed:27723720). Relocalizes to the nuclear envelope in response to CC mechanical stress or DNA damage (PubMed:25083873, PubMed:37832547). CC Also localizes to the micronuclear envelope in response to response to CC genome instability (PubMed:37788673). {ECO:0000269|PubMed:12814551, CC ECO:0000269|PubMed:25083873, ECO:0000269|PubMed:27723720, CC ECO:0000269|PubMed:37788673, ECO:0000269|PubMed:37832547}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q13535-1; Sequence=Displayed; CC Name=2; CC IsoId=Q13535-2; Sequence=VSP_013305, VSP_013304; CC Name=3; CC IsoId=Q13535-3; Sequence=VSP_036907, VSP_036908; CC -!- TISSUE SPECIFICITY: Ubiquitous, with highest expression in testis. CC {ECO:0000269|PubMed:11470508, ECO:0000269|PubMed:8610130, CC ECO:0000269|PubMed:8843195}. CC -!- TISSUE SPECIFICITY: [Isoform 2]: Isoform 2 is found in pancreas, CC placenta and liver but not in heart, testis and ovary. CC {ECO:0000269|PubMed:11470508}. CC -!- PTM: Phosphorylated (PubMed:21144835). Autophosphorylation at Thr-1989 CC in response to DNA damage promotes interaction with TOPBP1 and CC activation of ATR (PubMed:21705319, PubMed:21777809). CC {ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:21705319, CC ECO:0000269|PubMed:21777809}. CC -!- DISEASE: Seckel syndrome 1 (SCKL1) [MIM:210600]: A rare autosomal CC recessive disorder characterized by proportionate dwarfism of prenatal CC onset associated with low birth weight, growth retardation, severe CC microcephaly with a bird-headed like appearance, and intellectual CC disability. {ECO:0000269|PubMed:12640452}. Note=The disease is caused CC by variants affecting the gene represented in this entry. CC -!- DISEASE: Cutaneous telangiectasia and cancer syndrome, familial (FCTCS) CC [MIM:614564]: A disease characterized by cutaneous telangiectases in CC infancy with patchy alopecia over areas of affected skin, thinning of CC the lateral eyebrows, and mild dental and nail anomalies. Affected CC individuals are at increased risk of developing oropharyngeal cancer, CC and other malignancies have been reported as well. CC {ECO:0000269|PubMed:22341969}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. ATM subfamily. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/728/ATR"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Y09077; CAA70298.1; -; mRNA. DR EMBL; U76308; AAC50929.1; -; mRNA. DR EMBL; U49844; AAC50405.1; -; mRNA. DR EMBL; AF325699; AAK26749.1; -; Genomic_DNA. DR EMBL; AB208847; BAD92084.1; -; mRNA. DR CCDS; CCDS3124.1; -. [Q13535-1] DR CCDS; CCDS93402.1; -. [Q13535-2] DR RefSeq; NP_001175.2; NM_001184.4. [Q13535-1] DR RefSeq; NP_001341508.1; NM_001354579.2. [Q13535-2] DR PDB; 5YZ0; EM; 4.70 A; A/B=1-2644. DR PDB; 9L40; EM; 2.87 A; A/B=1-2644. DR PDB; 9L43; EM; 3.83 A; A/B=1-2644. DR PDB; 9L45; EM; 3.95 A; A/B=1-2644. DR PDB; 9L46; EM; 6.29 A; A/B=1-2644. DR PDB; 9L4B; EM; 3.20 A; A/B=1-2644. DR PDB; 9L4C; EM; 4.06 A; A/B=1-2644. DR PDB; 9L4D; EM; 3.79 A; A/B=8-2644. DR PDB; 9L4F; EM; 6.22 A; A/B=1-2644. DR PDBsum; 5YZ0; -. DR PDBsum; 9L40; -. DR PDBsum; 9L43; -. DR PDBsum; 9L45; -. DR PDBsum; 9L46; -. DR PDBsum; 9L4B; -. DR PDBsum; 9L4C; -. DR PDBsum; 9L4D; -. DR PDBsum; 9L4F; -. DR AlphaFoldDB; Q13535; -. DR EMDB; EMD-62801; -. DR EMDB; EMD-62804; -. DR EMDB; EMD-62806; -. DR EMDB; EMD-62807; -. DR EMDB; EMD-62808; -. DR EMDB; EMD-62809; -. DR EMDB; EMD-62811; -. DR EMDB; EMD-62812; -. DR EMDB; EMD-6862; -. DR SMR; Q13535; -. DR BioGRID; 107027; 243. DR ComplexPortal; CPX-3622; ATR-ATRIP DNA damage-sensing kinase complex. DR CORUM; Q13535; -. DR DIP; DIP-35308N; -. DR FunCoup; Q13535; 3607. DR IntAct; Q13535; 96. DR MINT; Q13535; -. DR STRING; 9606.ENSP00000343741; -. DR BindingDB; Q13535; -. DR ChEMBL; CHEMBL5024; -. DR DrugBank; DB11794; Berzosertib. DR DrugBank; DB14917; Ceralasertib. DR DrugBank; DB19041; Elimusertib. DR GuidetoPHARMACOLOGY; 1935; -. DR CarbonylDB; Q13535; -. DR GlyGen; Q13535; 3 sites, 1 O-linked glycan (2 sites). DR iPTMnet; Q13535; -. DR PhosphoSitePlus; Q13535; -. DR BioMuta; ATR; -. DR DMDM; 62286460; -. DR CPTAC; CPTAC-3214; -. DR CPTAC; CPTAC-3215; -. DR jPOST; Q13535; -. DR MassIVE; Q13535; -. DR PaxDb; 9606-ENSP00000343741; -. DR PeptideAtlas; Q13535; -. DR ProteomicsDB; 59521; -. [Q13535-1] DR ProteomicsDB; 59522; -. [Q13535-2] DR ProteomicsDB; 59523; -. [Q13535-3] DR Pumba; Q13535; -. DR Antibodypedia; 18078; 557 antibodies from 41 providers. DR CPTC; Q13535; 1 antibody. DR DNASU; 545; -. DR Ensembl; ENST00000350721.9; ENSP00000343741.4; ENSG00000175054.17. [Q13535-1] DR Ensembl; ENST00000661310.1; ENSP00000499589.1; ENSG00000175054.17. [Q13535-2] DR GeneID; 545; -. DR KEGG; hsa:545; -. DR MANE-Select; ENST00000350721.9; ENSP00000343741.4; NM_001184.4; NP_001175.2. DR UCSC; uc003eux.5; human. [Q13535-1] DR AGR; HGNC:882; -. DR CIViC; 545; 2 evidence items across 2 molecular profiles. DR ClinPGx; PA74; -. DR CTD; 545; -. DR DisGeNET; 545; -. DR GeneCards; ATR; -. DR HGNC; HGNC:882; ATR. DR HPA; ENSG00000175054; Low tissue specificity. DR MalaCards; ATR; -. DR MIM; 210600; phenotype. DR MIM; 601215; gene. DR MIM; 614564; phenotype. DR OpenTargets; ENSG00000175054; -. DR Orphanet; 313846; Familial cutaneous telangiectasia and oropharyngeal cancer predisposition syndrome. DR Orphanet; 808; Seckel syndrome. DR VEuPathDB; HostDB:ENSG00000175054; -. DR eggNOG; KOG0890; Eukaryota. DR GeneTree; ENSGT00940000155714; -. DR HOGENOM; CLU_000178_2_1_1; -. DR InParanoid; Q13535; -. DR OMA; SMYIGWC; -. DR OrthoDB; 381190at2759; -. DR PAN-GO; Q13535; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q13535; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q13535; -. DR Reactome; R-HSA-1221632; Meiotic synapsis. DR Reactome; R-HSA-176187; Activation of ATR in response to replication stress. DR Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response. DR Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA). DR Reactome; R-HSA-5693607; Processing of DNA double-strand break ends. DR Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange. DR Reactome; R-HSA-6783310; Fanconi Anemia Pathway. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-9709570; Impaired BRCA2 binding to RAD51. DR SignaLink; Q13535; -. DR SIGNOR; Q13535; -. DR Agora; ENSG00000175054; -. DR BioGRID-ORCS; 545; 746 hits in 1209 CRISPR screens. DR CD-CODE; 804901D1; Nuclear speckle. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; A0DCDA94; DNA damage foci. DR CD-CODE; B5B9A610; PML body. DR CD-CODE; D3B9EAFD; Synthetic Condensate 000362. DR ChiTaRS; ATR; human. DR GeneWiki; Ataxia_telangiectasia_and_Rad3_related; -. DR GenomeRNAi; 545; -. DR Pharos; Q13535; Tchem. DR PRO; PR:Q13535; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q13535; protein. DR Bgee; ENSG00000175054; Expressed in Brodmann (1909) area 23 and 205 other cell types or tissues. DR ExpressionAtlas; Q13535; baseline and differential. DR GO; GO:0070310; C:ATR-ATRIP complex; IPI:ComplexPortal. DR GO; GO:0005694; C:chromosome; ISS:UniProtKB. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0005635; C:nuclear envelope; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0016605; C:PML body; IDA:UniProtKB. DR GO; GO:0090734; C:site of DNA damage; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0035979; F:histone H2AXS139 kinase activity; IDA:UniProtKB. DR GO; GO:0032405; F:MutLalpha complex binding; IDA:MGI. DR GO; GO:0032407; F:MutSalpha complex binding; IDA:MGI. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:BHF-UCL. DR GO; GO:0034644; P:cellular response to UV; IMP:BHF-UCL. DR GO; GO:0000077; P:DNA damage checkpoint signaling; IDA:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0006281; P:DNA repair; IBA:GO_Central. DR GO; GO:0006260; P:DNA replication; TAS:Reactome. DR GO; GO:0006302; P:double-strand break repair; IDA:UniProt. DR GO; GO:0097695; P:establishment of protein-containing complex localization to telomere; IC:BHF-UCL. DR GO; GO:0097694; P:establishment of RNA localization to telomere; IMP:BHF-UCL. DR GO; GO:0036297; P:interstrand cross-link repair; TAS:Reactome. DR GO; GO:0044818; P:mitotic G2/M transition checkpoint; IDA:UniProt. DR GO; GO:0008156; P:negative regulation of DNA replication; IMP:UniProtKB. DR GO; GO:0051081; P:nuclear membrane disassembly; IDA:UniProtKB. DR GO; GO:0006139; P:nucleobase-containing compound metabolic process; NAS:ComplexPortal. DR GO; GO:0043517; P:positive regulation of DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL. DR GO; GO:1904884; P:positive regulation of telomerase catalytic core complex assembly; IMP:BHF-UCL. DR GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; ISS:BHF-UCL. DR GO; GO:0070198; P:protein localization to chromosome, telomeric region; IMP:BHF-UCL. DR GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome. DR GO; GO:2000779; P:regulation of double-strand break repair; NAS:ComplexPortal. DR GO; GO:0031297; P:replication fork processing; ISS:UniProtKB. DR GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL. DR GO; GO:0046685; P:response to arsenic-containing substance; IEA:Ensembl. DR GO; GO:0009612; P:response to mechanical stimulus; IDA:UniProtKB. DR GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0000723; P:telomere maintenance; IBA:GO_Central. DR CDD; cd00892; PIKKc_ATR; 1. DR FunFam; 1.10.1070.11:FF:000009; Putative serine/threonine-protein kinase ATR; 1. DR FunFam; 1.25.10.10:FF:000149; Serine/threonine-protein kinase ATR; 1. DR FunFam; 1.25.40.10:FF:000142; Serine/threonine-protein kinase ATR; 1. DR FunFam; 3.30.1010.10:FF:000011; serine/threonine-protein kinase ATR; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 2. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR Gene3D; 1.25.40.10; Tetratricopeptide repeat domain; 1. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR056802; ATR-like_M-HEAT. DR InterPro; IPR056803; ATR-like_N-HEAT. DR InterPro; IPR050517; DDR_Repair_Kinase. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR057564; HEAT_ATR. DR InterPro; IPR021133; HEAT_type_2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR InterPro; IPR011990; TPR-like_helical_dom_sf. DR InterPro; IPR012993; UME. DR PANTHER; PTHR11139; ATAXIA TELANGIECTASIA MUTATED ATM -RELATED; 1. DR PANTHER; PTHR11139:SF69; SERINE_THREONINE-PROTEIN KINASE ATR; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF02260; FATC; 1. DR Pfam; PF23593; HEAT_ATR; 1. DR Pfam; PF25030; M-HEAT_ATR; 1. DR Pfam; PF25032; N-HEAT_ATR; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR Pfam; PF08064; UME; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM00146; PI3Kc; 1. DR SMART; SM00802; UME; 1. DR SUPFAM; SSF48371; ARM repeat; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF48452; TPR-like; 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS50077; HEAT_REPEAT; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Chromosome; KW Disease variant; DNA damage; DNA repair; DNA-binding; Dwarfism; KW Intellectual disability; Kinase; Manganese; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..2644 FT /note="Serine/threonine-protein kinase ATR" FT /id="PRO_0000088844" FT REPEAT 799..835 FT /note="HEAT 1" FT REPEAT 1329..1365 FT /note="HEAT 2" FT DOMAIN 1640..2185 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT DOMAIN 2296..2604 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 2612..2644 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 418..450 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2302..2308 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2472..2480 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2492..2516 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT MOD_RES 428 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:21144835, FT ECO:0000269|PubMed:21777809, ECO:0007744|PubMed:18691976" FT MOD_RES 435 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:21777809, FT ECO:0007744|PubMed:23186163" FT MOD_RES 436 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1989 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:21705319, FT ECO:0000269|PubMed:21777809, ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 450 FT /note="E -> D (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11470508" FT /id="VSP_013305" FT VAR_SEQ 451..514 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:11470508" FT /id="VSP_013304" FT VAR_SEQ 2588..2610 FT /note="AKTHVLDIEQRLQGVIKTRNRVT -> VSRRYSLIWAVVLISTNELDMQL FT (in isoform 3)" FT /evidence="ECO:0000303|Ref.4" FT /id="VSP_036907" FT VAR_SEQ 2611..2644 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|Ref.4" FT /id="VSP_036908" FT VARIANT 64 FT /note="T -> A (in dbSNP:rs35306038)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041584" FT VARIANT 90 FT /note="H -> Y (in dbSNP:rs28897763)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041585" FT VARIANT 211 FT /note="M -> T (in dbSNP:rs2227928)" FT /id="VAR_050532" FT VARIANT 297 FT /note="K -> N (in dbSNP:rs2229033)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041586" FT VARIANT 316 FT /note="V -> I (in dbSNP:rs28897764)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041587" FT VARIANT 959 FT /note="V -> M (in dbSNP:rs28910271)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041588" FT VARIANT 1087 FT /note="Y -> H (in dbSNP:rs34253059)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041589" FT VARIANT 1213 FT /note="S -> G (in dbSNP:rs34766606)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041590" FT VARIANT 1488 FT /note="A -> P (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041591" FT VARIANT 1526 FT /note="I -> V (in dbSNP:rs34124242)" FT /id="VAR_050533" FT VARIANT 1607 FT /note="S -> N (in dbSNP:rs55724025)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041592" FT VARIANT 1612 FT /note="N -> S (in dbSNP:rs55894265)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041593" FT VARIANT 2002 FT /note="A -> G (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041594" FT VARIANT 2120 FT /note="G -> A (in dbSNP:rs35134774)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041595" FT VARIANT 2132 FT /note="Y -> D (in dbSNP:rs28910273)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041596" FT VARIANT 2144 FT /note="Q -> R (in FCTCS; dbSNP:rs387906797)" FT /evidence="ECO:0000269|PubMed:22341969" FT /id="VAR_067919" FT VARIANT 2233 FT /note="S -> I (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041597" FT VARIANT 2425 FT /note="R -> Q (in dbSNP:rs2229032)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041598" FT VARIANT 2434 FT /note="P -> A (in dbSNP:rs33972295)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041599" FT VARIANT 2438 FT /note="E -> K (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation; dbSNP:rs2108261462)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041600" FT VARIANT 2537 FT /note="E -> Q (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041601" FT MUTAGEN 1989 FT /note="T->A: Impaired autophosphorylation, leading to FT decreased activation of ATR." FT /evidence="ECO:0000269|PubMed:21705319" FT MUTAGEN 2327 FT /note="K->R: Abolishes kinase activity." FT /evidence="ECO:0000269|PubMed:11114888, FT ECO:0000269|PubMed:12011431, ECO:0000269|PubMed:9925639" FT MUTAGEN 2475 FT /note="D->A: Abolishes kinase activity; increases FT sensitivity to IR and impairs translocation to nuclear foci FT upon DNA damage." FT /evidence="ECO:0000269|PubMed:12814551, FT ECO:0000269|PubMed:9427750, ECO:0000269|PubMed:9925639" FT MUTAGEN 2494 FT /note="D->E: Abolishes kinase activity; reduces cell FT viability, augments sensitivity to IR and UV." FT /evidence="ECO:0000269|PubMed:10597277, FT ECO:0000269|PubMed:9636169" FT CONFLICT 92 FT /note="A -> R (in Ref. 1; CAA70298/AAC50929)" FT /evidence="ECO:0000305" SQ SEQUENCE 2644 AA; 301367 MW; 11BC22297FB9A802 CRC64; MGEHGLELAS MIPALRELGS ATPEEYNTVV QKPRQILCQF IDRILTDVNV VAVELVKKTD SQPTSVMLLD FIQHIMKSSP LMFVNVSGSH EAKGSCIEFS NWIITRLLRI AATPSCHLLH KKICEVICSL LFLFKSKSPA IFGVLTKELL QLFEDLVYLH RRNVMGHAVE WPVVMSRFLS QLDEHMGYLQ SAPLQLMSMQ NLEFIEVTLL MVLTRIIAIV FFRRQELLLW QIGCVLLEYG SPKIKSLAIS FLTELFQLGG LPAQPASTFF SSFLELLKHL VEMDTDQLKL YEEPLSKLIK TLFPFEAEAY RNIEPVYLNM LLEKLCVMFE DGVLMRLKSD LLKAALCHLL QYFLKFVPAG YESALQVRKV YVRNICKALL DVLGIEVDAE YLLGPLYAAL KMESMEIIEE IQCQTQQENL SSNSDGISPK RRRLSSSLNP SKRAPKQTEE IKHVDMNQKS ILWSALKQKA ESLQISLEYS GLKNPVIEML EGIAVVLQLT ALCTVHCSHQ NMNCRTFKDC QHKSKKKPSV VITWMSLDFY TKVLKSCRSL LESVQKLDLE ATIDKVVKIY DALIYMQVNS SFEDHILEDL CGMLSLPWIY SHSDDGCLKL TTFAANLLTL SCRISDSYSP QAQSRCVFLL TLFPRRIFLE WRTAVYNWAL QSSHEVIRAS CVSGFFILLQ QQNSCNRVPK ILIDKVKDDS DIVKKEFASI LGQLVCTLHG MFYLTSSLTE PFSEHGHVDL FCRNLKATSQ HECSSSQLKA SVCKPFLFLL KKKIPSPVKL AFIDNLHHLC KHLDFREDET DVKAVLGTLL NLMEDPDKDV RVAFSGNIKH ILESLDSEDG FIKELFVLRM KEAYTHAQIS RNNELKDTLI LTTGDIGRAA KGDLVPFALL HLLHCLLSKS ASVSGAAYTE IRALVAAKSV KLQSFFSQYK KPICQFLVES LHSSQMTALP NTPCQNADVR KQDVAHQREM ALNTLSEIAN VFDFPDLNRF LTRTLQVLLP DLAAKASPAA SALIRTLGKQ LNVNRREILI NNFKYIFSHL VCSCSKDELE RALHYLKNET EIELGSLLRQ DFQGLHNELL LRIGEHYQQV FNGLSILASF ASSDDPYQGP RDIISPELMA DYLQPKLLGI LAFFNMQLLS SSVGIEDKKM ALNSLMSLMK LMGPKHVSSV RVKMMTTLRT GLRFKDDFPE LCCRAWDCFV RCLDHACLGS LLSHVIVALL PLIHIQPKET AAIFHYLIIE NRDAVQDFLH EIYFLPDHPE LKKIKAVLQE YRKETSESTD LQTTLQLSMK AIQHENVDVR IHALTSLKET LYKNQEKLIK YATDSETVEP IISQLVTVLL KGCQDANSQA RLLCGECLGE LGAIDPGRLD FSTTETQGKD FTFVTGVEDS SFAYGLLMEL TRAYLAYADN SRAQDSAAYA IQELLSIYDC REMETNGPGH QLWRRFPEHV REILEPHLNT RYKSSQKSTD WSGVKKPIYL SKLGSNFAEW SASWAGYLIT KVRHDLASKI FTCCSIMMKH DFKVTIYLLP HILVYVLLGC NQEDQQEVYA EIMAVLKHDD QHTINTQDIA SDLCQLSTQT VFSMLDHLTQ WARHKFQALK AEKCPHSKSN RNKVDSMVST VDYEDYQSVT RFLDLIPQDT LAVASFRSKA YTRAVMHFES FITEKKQNIQ EHLGFLQKLY AAMHEPDGVA GVSAIRKAEP SLKEQILEHE SLGLLRDATA CYDRAIQLEP DQIIHYHGVV KSMLGLGQLS TVITQVNGVH ANRSEWTDEL NTYRVEAAWK LSQWDLVENY LAADGKSTTW SVRLGQLLLS AKKRDITAFY DSLKLVRAEQ IVPLSAASFE RGSYQRGYEY IVRLHMLCEL EHSIKPLFQH SPGDSSQEDS LNWVARLEMT QNSYRAKEPI LALRRALLSL NKRPDYNEMV GECWLQSARV ARKAGHHQTA YNALLNAGES RLAELYVERA KWLWSKGDVH QALIVLQKGV ELCFPENETP PEGKNMLIHG RAMLLVGRFM EETANFESNA IMKKYKDVTA CLPEWEDGHF YLAKYYDKLM PMVTDNKMEK QGDLIRYIVL HFGRSLQYGN QFIYQSMPRM LTLWLDYGTK AYEWEKAGRS DRVQMRNDLG KINKVITEHT NYLAPYQFLT AFSQLISRIC HSHDEVFVVL MEIIAKVFLA YPQQAMWMMT AVSKSSYPMR VNRCKEILNK AIHMKKSLEK FVGDATRLTD KLLELCNKPV DGSSSTLSMS THFKMLKKLV EEATFSEILI PLQSVMIPTL PSILGTHANH ASHEPFPGHW AYIAGFDDMV EILASLQKPK KISLKGSDGK FYIMMCKPKD DLRKDCRLME FNSLINKCLR KDAESRRREL HIRTYAVIPL NDECGIIEWV NNTAGLRPIL TKLYKEKGVY MTGKELRQCM LPKSAALSEK LKVFREFLLP RHPPIFHEWF LRTFPDPTSW YSSRSAYCRS TAVMSMVGYI LGLGDRHGEN ILFDSLTGEC VHVDFNCLFN KGETFEVPEI VPFRLTHNMV NGMGPMGTEG LFRRACEVTM RLMRDQREPL MSVLKTFLHD PLVEWSKPVK GHSKAPLNET GEVVNEKAKT HVLDIEQRLQ GVIKTRNRVT GLPLSIEGHV HYLIQEATDE NLLCQMYLGW TPYM // ID BRAF_HUMAN Reviewed; 766 AA. AC P15056; A4D1T4; B6HY61; B6HY62; B6HY63; B6HY64; B6HY65; B6HY66; Q13878; AC Q3MIN6; Q9UDP8; Q9Y6T3; DT 01-NOV-1990, integrated into UniProtKB/Swiss-Prot. DT 19-JUL-2004, sequence version 4. DT 28-JAN-2026, entry version 267. DE RecName: Full=Serine/threonine-protein kinase B-raf {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126}; DE AltName: Full=Proto-oncogene B-Raf; DE AltName: Full=p94; DE AltName: Full=v-Raf murine sarcoma viral oncogene homolog B1; GN Name=BRAF {ECO:0000312|HGNC:HGNC:1097}; Synonyms=BRAF1, RAFB1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, FUNCTION, AND RP PHOSPHORYLATION AT THR-373. RC TISSUE=Testis; RX PubMed=1508179; DOI=10.1128/mcb.12.9.3733-3742.1992; RA Stephens R.M., Sithanandam G., Copeland T.D., Kaplan D.R., Rapp U.R., RA Morrison D.K.; RT "95-kilodalton B-Raf serine/threonine kinase: identification of the protein RT and its major autophosphorylation site."; RL Mol. Cell. Biol. 12:3733-3742(1992). RN [2] RP SEQUENCE REVISION TO 31-33. RA Albert S., Wixler L., Rapp U.R.; RL Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (MAR-2008) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Liver; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-200. RC TISSUE=Placenta; RX PubMed=1630826; RA Eychene A., Barnier J.V., Apiou F., Dutrillaux B., Calothy G.; RT "Chromosomal assignment of two human B-raf(Rmil) proto-oncogene loci: B- RT raf-1 encoding the p94Braf/Rmil and B-raf-2, a processed pseudogene."; RL Oncogene 7:1657-1660(1992). RN [8] RP PROTEIN SEQUENCE OF 2-51; 56-95; 151-158; 189-199; 253-260; 294-354; RP 361-424; 444-507; 510-522; 559-570; 579-626; 663-680; 692-698; 702-719; RP 727-735 AND 753-766, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT RP ALA-2, PHOSPHORYLATION AT SER-365; THR-396; SER-399; THR-401 AND SER-729, RP AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Colon carcinoma, and Hepatoma; RA Bienvenut W.V., Boldt K., von Kriegsheim A.F., Zebisch A., Kolch W.; RL Submitted (DEC-2008) to UniProtKB. RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 117-766. RC TISSUE=Testis; RX PubMed=2284096; RA Sithanandam G., Kolch W., Duh F.-M., Rapp U.R.; RT "Complete coding sequence of a human B-raf cDNA and detection of B-raf RT protein kinase with isozyme specific antibodies."; RL Oncogene 5:1775-1780(1990). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 381-766, DISEASE, AND CHROMOSOMAL RP REARRANGEMENT. RC TISSUE=Brain; RX PubMed=18974108; DOI=10.1158/0008-5472.can-08-2097; RA Jones D.T.W., Kocialkowski S., Liu L., Pearson D.M., Backlund L.M., RA Ichimura K., Collins V.P.; RT "Tandem duplication producing a novel oncogenic BRAF fusion gene defines RT the majority of pilocytic astrocytomas."; RL Cancer Res. 68:8673-8677(2008). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 439-766. RX PubMed=3043188; DOI=10.1128/mcb.8.6.2651-2654.1988; RA Ikawa S., Fukui M., Ueyama Y., Tamaoki N., Yamamoto T., Toyoshima K.; RT "B-raf, a new member of the raf family, is activated by DNA RT rearrangement."; RL Mol. Cell. Biol. 8:2651-2654(1988). RN [12] RP PHOSPHORYLATION AT SER-365 BY SGK1. RX PubMed=11410590; DOI=10.1074/jbc.m102808200; RA Zhang B.H., Tang E.D., Zhu T., Greenberg M.E., Vojtek A.B., Guan K.L.; RT "Serum- and glucocorticoid-inducible kinase SGK phosphorylates and RT negatively regulates B-Raf."; RL J. Biol. Chem. 276:31620-31626(2001). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401; SER-446; SER-447 AND RP SER-729, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [16] RP SUBUNIT, INTERACTION WITH DGKH, SUBCELLULAR LOCATION, AND PHOSPHORYLATION RP AT THR-753 BY MAPK1. RX PubMed=19710016; DOI=10.1074/jbc.m109.043604; RA Yasuda S., Kai M., Imai S., Takeishi K., Taketomi A., Toyota M., Kanoh H., RA Sakane F.; RT "Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf RT heterodimerization."; RL J. Biol. Chem. 284:29559-29570(2009). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [18] RP INTERACTION WITH AKAP13; MAP2K1 AND KSR1. RX PubMed=21102438; DOI=10.1038/ncb2130; RA Smith F.D., Langeberg L.K., Cellurale C., Pawson T., Morrison D.K., RA Davis R.J., Scott J.D.; RT "AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade."; RL Nat. Cell Biol. 12:1242-1249(2010). RN [19] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [20] RP INTERACTION WITH KSR2, SUBUNIT, CATALYTIC ACTIVITY, FUNCTION, AND RP MUTAGENESIS OF LYS-483. RX PubMed=21441910; DOI=10.1038/nature09860; RA Brennan D.F., Dar A.C., Hertz N.T., Chao W.C., Burlingame A.L., RA Shokat K.M., Barford D.; RT "A Raf-induced allosteric transition of KSR stimulates phosphorylation of RT MEK."; RL Nature 472:366-369(2011). RN [21] RP INTERACTION WITH PRMT5, METHYLATION AT ARG-671, CHARACTERIZATION OF VARIANT RP CRC GLU-600, AND MUTAGENESIS OF ARG-671. RX PubMed=21917714; DOI=10.1126/scisignal.2001936; RA Andreu-Perez P., Esteve-Puig R., de Torre-Minguela C., Lopez-Fauqued M., RA Bech-Serra J.J., Tenbaum S., Garcia-Trevijano E.R., Canals F., Merlino G., RA Avila M.A., Recio J.A.; RT "Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction RT amplitude and cell fate through CRAF."; RL Sci. Signal. 4:RA58-RA58(2011). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-729, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [23] RP UBIQUITINATION BY RNF149. RX PubMed=22628551; DOI=10.1074/jbc.m111.319822; RA Hong S.W., Jin D.H., Shin J.S., Moon J.H., Na Y.S., Jung K.A., Kim S.M., RA Kim J.C., Kim K.P., Hong Y.S., Lee J.L., Choi E.K., Lee J.S., Kim T.W.; RT "Ring finger protein 149 is an E3 ubiquitin ligase active on wild-type v- RT Raf murine sarcoma viral oncogene homolog B1 (BRAF)."; RL J. Biol. Chem. 287:24017-24025(2012). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151; SER-365; THR-401; RP SER-446 AND SER-729, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [25] RP UBIQUITINATION AT LYS-578, AND MUTAGENESIS OF LYS-578. RX PubMed=23907581; DOI=10.1038/srep02344; RA An L., Jia W., Yu Y., Zou N., Liang L., Zhao Y., Fan Y., Cheng J., Shi Z., RA Xu G., Li G., Yang J., Zhang H.; RT "Lys63-linked polyubiquitination of BRAF at lysine 578 is required for RT BRAF-mediated signaling."; RL Sci. Rep. 3:2344-2344(2013). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [27] RP INTERACTION WITH FNIP1 AND FNIP2. RX PubMed=27353360; DOI=10.1038/ncomms12037; RA Woodford M.R., Dunn D.M., Blanden A.R., Capriotti D., Loiselle D., RA Prodromou C., Panaretou B., Hughes P.F., Smith A., Ackerman W., RA Haystead T.A., Loh S.N., Bourboulia D., Schmidt L.S., Marston Linehan W., RA Bratslavsky G., Mollapour M.; RT "The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance RT drug binding."; RL Nat. Commun. 7:12037-12037(2016). RN [28] RP INTERACTION WITH YWHAZ. RX PubMed=31024343; DOI=10.3389/fphys.2019.00388; RA Popov I.K., Hiatt S.M., Whalen S., Keren B., Ruivenkamp C., RA van Haeringen A., Chen M.J., Cooper G.M., Korf B.R., Chang C.; RT "A YWHAZ variant associated with cardiofaciocutaneous syndrome activates RT the RAF-ERK pathway."; RL Front. Physiol. 10:388-388(2019). RN [29] RP FUNCTION, AND SUBUNIT. RX PubMed=36402789; DOI=10.1038/s41467-022-34907-0; RA McGrail K., Granado-Martinez P., Esteve-Puig R., Garcia-Ortega S., Ding Y., RA Sanchez-Redondo S., Ferrer B., Hernandez-Losa J., Canals F., Manzano A., RA Navarro-Sabate A., Bartrons R., Yanes O., Perez-Alea M., Munoz-Couselo E., RA Garcia-Patos V., Recio J.A.; RT "BRAF activation by metabolic stress promotes glycolysis sensitizing RT NRASQ61-mutated melanomas to targeted therapy."; RL Nat. Commun. 13:7113-7113(2022). RN [30] RP DEPHOSPHORYLATION AT SER-365 BY SMP COMPLEX. RX PubMed=35768504; DOI=10.1038/s41586-022-04838-3; RA Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., RA Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.; RT "Structural basis for SHOC2 modulation of RAS signalling."; RL Nature 609:400-407(2022). RN [31] RP DEPHOSPHORYLATION AT SER-365 BY SMP COMPLEX. RX PubMed=35830882; DOI=10.1038/s41586-022-05086-1; RA Hauseman Z.J., Fodor M., Dhembi A., Viscomi J., Egli D., Bleu M., Katz S., RA Park E., Jang D.M., Porter K.A., Meili F., Guo H., Kerr G., Molle S., RA Velez-Vega C., Beyer K.S., Galli G.G., Maira S.M., Stams T., Clark K., RA Eck M.J., Tordella L., Thoma C.R., King D.A.; RT "Structure of the MRAS-SHOC2-PP1C phosphatase complex."; RL Nature 609:416-423(2022). RN [32] RP X-RAY CRYSTALLOGRAPHY (2.57 ANGSTROMS) OF 444-719 IN COMPLEX WITH RP INHIBITOR. RX PubMed=18287029; DOI=10.1073/pnas.0711741105; RA Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., RA Gillette S., Kong J., Haass N.K., Sproesser K., Li L., Smalley K.S., RA Fong D., Zhu Y.L., Marimuthu A., Nguyen H., Lam B., Liu J., Cheung I., RA Rice J., Suzuki Y., Luu C., Settachatgul C., Shellooe R., Cantwell J., RA Kim S.H., Schlessinger J., Zhang K.Y., West B.L., Powell B., Habets G., RA Zhang C., Ibrahim P.N., Hirth P., Artis D.R., Herlyn M., Bollag G.; RT "Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent RT antimelanoma activity."; RL Proc. Natl. Acad. Sci. U.S.A. 105:3041-3046(2008). RN [33] {ECO:0007744|PDB:5VR3, ECO:0007744|PDB:5VYK} RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 36-110, FUNCTION, CATALYTIC RP ACTIVITY, ACTIVITY REGULATION, INTERACTION WITH KSR1; KSR2; MAP2K1 AND RP MAP2K2, AND MUTAGENESIS OF MET-53; LYS-88; ARG-509 AND ILE-666. RX PubMed=29433126; DOI=10.1038/nature25478; RA Lavoie H., Sahmi M., Maisonneuve P., Marullo S.A., Thevakumaran N., Jin T., RA Kurinov I., Sicheri F., Therrien M.; RT "MEK drives BRAF activation through allosteric control of KSR proteins."; RL Nature 554:549-553(2018). RN [34] RP VARIANTS LNCR VAL-466 AND ARG-597. RX PubMed=12460919; RA Naoki K., Chen T.-H., Richards W.G., Sugarbaker D.J., Meyerson M.; RT "Missense mutations of the BRAF gene in human lung adenocarcinoma."; RL Cancer Res. 62:7001-7003(2002). RN [35] RP VARIANTS CANCER GLU-464; VAL-464; ALA-466; GLU-466; VAL-466; ALA-469; RP GLU-469; LYS-586; LEU-595; ARG-596; ARG-597; VAL-597; GLU-600 AND ASP-600, RP AND CHARACTERIZATION OF VARIANTS CANCER VAL-464; ALA-469; VAL-597 AND RP GLU-600. RX PubMed=12068308; DOI=10.1038/nature00766; RA Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., RA Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., RA Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., RA Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., RA Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., RA Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., RA Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W.C., RA Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., RA Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.; RT "Mutations of the BRAF gene in human cancer."; RL Nature 417:949-954(2002). RN [36] RP VARIANTS CRC ILE-462; SER-463; GLU-464; GLU-600 AND GLU-601. RX PubMed=12198537; DOI=10.1038/418934a; RA Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., RA Velculescu V.E.; RT "Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status."; RL Nature 418:934-934(2002). RN [37] RP VARIANTS NHL ALA-469; ARG-469 AND GLY-594. RX PubMed=14612909; DOI=10.1038/sj.bjc.6601371; RA Lee J.W., Yoo N.J., Soung Ark W.S., Kim S.Y., Lee J.H., Park J.Y., RA Cho Y.G., Kim C.J., Ko Y.H., Kim S.H., Nam S.W., Lee J.Y., Lee S.H.; RT "BRAF mutations in non-Hodgkin's lymphoma."; RL Br. J. Cancer 89:1958-1960(2003). RN [38] RP CHARACTERIZATION OF VARIANT MELANOMA GLU-600. RX PubMed=14500344; RA Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M., Tuveson D.A.; RT "Suppression of BRAF(V599E) in human melanoma abrogates transformation."; RL Cancer Res. 63:5198-5202(2003). RN [39] RP VARIANTS CFC1 PRO-246; ARG-257; GLU-469; PHE-485; GLU-499; LYS-501; GLY-501 RP AND ASP-581. RX PubMed=16474404; DOI=10.1038/ng1749; RA Niihori T., Aoki Y., Narumi Y., Neri G., Cave H., Verloes A., Okamoto N., RA Hennekam R.C.M., Gillessen-Kaesbach G., Wieczorek D., Kavamura M.I., RA Kurosawa K., Ohashi H., Wilson L., Heron D., Bonneau D., Corona G., RA Kaname T., Naritomi K., Baumann C., Matsumoto N., Kato K., Kure S., RA Matsubara Y.; RT "Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome."; RL Nat. Genet. 38:294-296(2006). RN [40] RP VARIANT [LARGE SCALE ANALYSIS] GLU-600. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [41] RP VARIANTS CFC1 ARG-257; ALA-467; SER-468; GLU-469; PHE-485; GLU-499; RP LYS-501; GLY-501; ASP-581; LEU-595 AND VAL-596. RX PubMed=16439621; DOI=10.1126/science.1124642; RA Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A., RA Cruz M.S., McCormick F., Rauen K.A.; RT "Germline mutations in genes within the MAPK pathway cause cardio-facio- RT cutaneous syndrome."; RL Science 311:1287-1290(2006). RN [42] RP VARIANTS [LARGE SCALE ANALYSIS] SER-301; ALA-469; VAL-469; SER-581; RP ARG-596; ARG-597; VAL-597 AND GLU-600. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [43] RP VARIANTS CFC1 PRO-241; PRO-244; PRO-246; ARG-257; LYS-262; SER-468; RP GLU-469; GLU-499; ASN-499; ASP-580; ASP-581 AND LEU-595. RX PubMed=18042262; DOI=10.1111/j.1399-0004.2007.00931.x; RA Schulz A.L., Albrecht B., Arici C., van der Burgt I., Buske A., RA Gillessen-Kaesbach G., Heller R., Horn D., Hubner C.A., Korenke G.C., RA Konig R., Kress W., Kruger G., Meinecke P., Mucke J., Plecko B., RA Rossier E., Schinzel A., Schulze A., Seemanova E., Seidel H., Spranger S., RA Tuysuz B., Uhrig S., Wieczorek D., Kutsche K., Zenker M.; RT "Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous RT and Costello syndrome."; RL Clin. Genet. 73:62-70(2008). RN [44] RP VARIANT LPRD3 PRO-241, VARIANTS NS7 ARG-241; MET-241; CYS-531 AND VAL-597, RP AND VARIANTS CFC1 PHE-245; PRO-246; ARG-257; LYS-275; GLU-469; PHE-485; RP ASN-499; LYS-501; PRO-525; LEU-595; ARG-599; GLN-601; GLU-638 AND ARG-709. RX PubMed=19206169; DOI=10.1002/humu.20955; RA Sarkozy A., Carta C., Moretti S., Zampino G., Digilio M.C., Pantaleoni F., RA Scioletti A.P., Esposito G., Cordeddu V., Lepri F., Petrangeli V., RA Dentici M.L., Mancini G.M., Selicorni A., Rossi C., Mazzanti L., Marino B., RA Ferrero G.B., Silengo M.C., Memo L., Stanzial F., Faravelli F., Stuppia L., RA Puxeddu E., Gelb B.D., Dallapiccola B., Tartaglia M.; RT "Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous RT syndromes: molecular diversity and associated phenotypic spectrum."; RL Hum. Mutat. 30:695-702(2009). RN [45] RP VARIANT CRC GLU-600. RX PubMed=23263490; DOI=10.1038/ng.2503; RG CORGI Consortium; RG WGS500 Consortium; RA Palles C., Cazier J.B., Howarth K.M., Domingo E., Jones A.M., Broderick P., RA Kemp Z., Spain S.L., Guarino Almeida E., Salguero I., Sherborne A., RA Chubb D., Carvajal-Carmona L.G., Ma Y., Kaur K., Dobbins S., Barclay E., RA Gorman M., Martin L., Kovac M.B., Humphray S., Lucassen A., Holmes C.C., RA Bentley D., Donnelly P., Taylor J., Petridis C., Roylance R., Sawyer E.J., RA Kerr D.J., Clark S., Grimes J., Kearsey S.E., Thomas H.J., McVean G., RA Houlston R.S., Tomlinson I.; RT "Germline mutations affecting the proofreading domains of POLE and POLD1 RT predispose to colorectal adenomas and carcinomas."; RL Nat. Genet. 45:136-144(2013). RN [46] RP VARIANT CRC GLU-600. RX PubMed=24455489; DOI=10.3389/fonc.2013.00333; RA D'mello S.A., Flanagan J.U., Green T.N., Leung E.Y., Askarian-Amiri M.E., RA Joseph W.R., McCrystal M.R., Isaacs R.J., Shaw J.H., Furneaux C.E., RA During M.J., Finlay G.J., Baguley B.C., Kalev-Zylinska M.L.; RT "Evidence that GRIN2A mutations in melanoma correlate with decreased RT survival."; RL Front. Oncol. 3:333-333(2014). CC -!- FUNCTION: Protein kinase involved in the transduction of mitogenic CC signals from the cell membrane to the nucleus (Probable). CC Phosphorylates MAP2K1, and thereby activates the MAP kinase signal CC transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates CC PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses CC of hippocampal neurons (PubMed:1508179). {ECO:0000269|PubMed:1508179, CC ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126, CC ECO:0000269|PubMed:36402789, ECO:0000305}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21441910}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250}; CC Note=Binds 2 Zn(2+) ions per subunit. {ECO:0000250}; CC -!- ACTIVITY REGULATION: In quiescent cells, maintained in an inactive CC state via an intramolecular interaction between the protein kinase and CC N-terminal domains. Following mitogen-mediated cell activation, binds CC via its RGB domain to active HRAS (GTP-bound) which releases the CC inhibitory intramolecular interaction between the two domains. This CC allows the MAP2K1-mediated dimerization of KSR1 or KSR2, and BRAF which CC activates BRAF. {ECO:0000269|PubMed:29433126}. CC -!- SUBUNIT: Monomer (PubMed:19710016). Homodimer (PubMed:19710016, CC PubMed:36402789). Heterodimerizes with RAF1, and the heterodimer CC possesses a highly increased kinase activity compared to the respective CC homodimers or monomers (PubMed:19710016). Heterodimerization is CC mitogen-regulated and enhanced by 14-3-3 proteins. MAPK1/ERK2 CC activation can induce a negative feedback that promotes the CC dissociation of the heterodimer by phosphorylating BRAF at Thr-753. CC Heterodimerizes (via N-terminus) with KSR1 (via N-terminus) or KSR2 CC (via N-terminus) in a MAP2K1-dependent manner (PubMed:29433126). CC Interacts with MAP2K1 and MAP2K2 (PubMed:29433126). Found in a complex CC with at least BRAF, HRAS, MAP2K1, MAPK3 and RGS14. Interacts with RIT1. CC Interacts (via N-terminus) with RGS14 (via RBD domains); the CC interaction mediates the formation of a ternary complex with RAF1, a CC ternary complex inhibited by GNAI1 (By similarity). Interacts with DGKH CC (PubMed:19710016). Interacts with PRMT5 (PubMed:21917714). Interacts CC with KSR2 (PubMed:21441910). Interacts with AKAP13, MAP2K1 and KSR1. CC Identified in a complex with AKAP13, MAP2K1 and KSR1 (PubMed:21102438). CC Interacts with FNIP1 and FNIP2 (PubMed:27353360). {ECO:0000250, CC ECO:0000269|PubMed:18287029, ECO:0000269|PubMed:19710016, CC ECO:0000269|PubMed:21102438, ECO:0000269|PubMed:21441910, CC ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:27353360, CC ECO:0000269|PubMed:29433126, ECO:0000269|PubMed:36402789}. CC -!- INTERACTION: CC P15056; P21399: ACO1; NbExp=4; IntAct=EBI-365980, EBI-2847111; CC P15056; P31749: AKT1; NbExp=4; IntAct=EBI-365980, EBI-296087; CC P15056; P10398: ARAF; NbExp=9; IntAct=EBI-365980, EBI-365961; CC P15056; P49407: ARRB1; NbExp=4; IntAct=EBI-365980, EBI-743313; CC P15056; O14965: AURKA; NbExp=5; IntAct=EBI-365980, EBI-448680; CC P15056; P25311: AZGP1; NbExp=3; IntAct=EBI-365980, EBI-2513837; CC P15056; Q92560: BAP1; NbExp=4; IntAct=EBI-365980, EBI-1791447; CC P15056; Q07817: BCL2L1; NbExp=7; IntAct=EBI-365980, EBI-78035; CC P15056; Q92843: BCL2L2; NbExp=4; IntAct=EBI-365980, EBI-707714; CC P15056; P15056: BRAF; NbExp=14; IntAct=EBI-365980, EBI-365980; CC P15056; P40259: CD79B; NbExp=3; IntAct=EBI-365980, EBI-2873732; CC P15056; Q6P1J9: CDC73; NbExp=4; IntAct=EBI-365980, EBI-930143; CC P15056; P42772: CDKN2B; NbExp=4; IntAct=EBI-365980, EBI-711280; CC P15056; P61024: CKS1B; NbExp=4; IntAct=EBI-365980, EBI-456371; CC P15056; P35221: CTNNA1; NbExp=4; IntAct=EBI-365980, EBI-701918; CC P15056; Q13618: CUL3; NbExp=2; IntAct=EBI-365980, EBI-456129; CC P15056; Q16254: E2F4; NbExp=4; IntAct=EBI-365980, EBI-448943; CC P15056; Q9GZV4: EIF5A2; NbExp=4; IntAct=EBI-365980, EBI-748028; CC P15056; Q7Z589: EMSY; NbExp=4; IntAct=EBI-365980, EBI-6598631; CC P15056; P18074: ERCC2; NbExp=3; IntAct=EBI-365980, EBI-6380590; CC P15056; P28715: ERCC5; NbExp=3; IntAct=EBI-365980, EBI-765885; CC P15056; O43524: FOXO3; NbExp=5; IntAct=EBI-365980, EBI-1644164; CC P15056; Q8WXI9: GATAD2B; NbExp=3; IntAct=EBI-365980, EBI-923440; CC P15056; P17174: GOT1; NbExp=5; IntAct=EBI-365980, EBI-727329; CC P15056; P49840: GSK3A; NbExp=6; IntAct=EBI-365980, EBI-1044067; CC P15056; O95714: HERC2; NbExp=2; IntAct=EBI-365980, EBI-1058922; CC P15056; P01112: HRAS; NbExp=9; IntAct=EBI-365980, EBI-350145; CC P15056; P08238: HSP90AB1; NbExp=5; IntAct=EBI-365980, EBI-352572; CC P15056; O75874: IDH1; NbExp=4; IntAct=EBI-365980, EBI-715695; CC P15056; O14920: IKBKB; NbExp=5; IntAct=EBI-365980, EBI-81266; CC P15056; P46940: IQGAP1; NbExp=4; IntAct=EBI-365980, EBI-297509; CC P15056; P27987: ITPKB; NbExp=4; IntAct=EBI-365980, EBI-751388; CC P15056; Q14145: KEAP1; NbExp=16; IntAct=EBI-365980, EBI-751001; CC P15056; Q02750: MAP2K1; NbExp=65; IntAct=EBI-365980, EBI-492564; CC P15056; P36507: MAP2K2; NbExp=13; IntAct=EBI-365980, EBI-1056930; CC P15056; Q13233: MAP3K1; NbExp=2; IntAct=EBI-365980, EBI-49776; CC P15056; Q15759: MAPK11; NbExp=4; IntAct=EBI-365980, EBI-298304; CC P15056; Q16659: MAPK6; NbExp=3; IntAct=EBI-365980, EBI-1384105; CC P15056; Q13164: MAPK7; NbExp=5; IntAct=EBI-365980, EBI-1213983; CC P15056; Q9NX70: MED29; NbExp=4; IntAct=EBI-365980, EBI-394656; CC P15056; O00255: MEN1; NbExp=4; IntAct=EBI-365980, EBI-592789; CC P15056; P07196: NEFL; NbExp=4; IntAct=EBI-365980, EBI-475646; CC P15056; P01111: NRAS; NbExp=8; IntAct=EBI-365980, EBI-721993; CC P15056; Q9BRP1: PDCD2L; NbExp=6; IntAct=EBI-365980, EBI-2372173; CC P15056; P48736: PIK3CG; NbExp=4; IntAct=EBI-365980, EBI-1030384; CC P15056; P27986: PIK3R1; NbExp=3; IntAct=EBI-365980, EBI-79464; CC P15056; P16885: PLCG2; NbExp=4; IntAct=EBI-365980, EBI-617403; CC P15056; Q07864: POLE; NbExp=6; IntAct=EBI-365980, EBI-348526; CC P15056; O15297: PPM1D; NbExp=4; IntAct=EBI-365980, EBI-1551512; CC P15056; Q02156: PRKCE; NbExp=3; IntAct=EBI-365980, EBI-706254; CC P15056; P57735: RAB25; NbExp=4; IntAct=EBI-365980, EBI-1050500; CC P15056; P04049: RAF1; NbExp=73; IntAct=EBI-365980, EBI-365996; CC P15056; Q12967: RALGDS; NbExp=4; IntAct=EBI-365980, EBI-365861; CC P15056; P61224: RAP1B; NbExp=4; IntAct=EBI-365980, EBI-358143; CC P15056; Q15349: RPS6KA2; NbExp=2; IntAct=EBI-365980, EBI-1384149; CC P15056; Q8N122: RPTOR; NbExp=4; IntAct=EBI-365980, EBI-1567928; CC P15056; Q8IYM1: SEPTIN12; NbExp=4; IntAct=EBI-365980, EBI-2585067; CC P15056; P31947: SFN; NbExp=6; IntAct=EBI-365980, EBI-476295; CC P15056; Q9UMX1: SUFU; NbExp=4; IntAct=EBI-365980, EBI-740595; CC P15056; P04637: TP53; NbExp=4; IntAct=EBI-365980, EBI-366083; CC P15056; Q13114: TRAF3; NbExp=2; IntAct=EBI-365980, EBI-357631; CC P15056; P40337: VHL; NbExp=7; IntAct=EBI-365980, EBI-301246; CC P15056; P31946: YWHAB; NbExp=14; IntAct=EBI-365980, EBI-359815; CC P15056; P62258: YWHAE; NbExp=11; IntAct=EBI-365980, EBI-356498; CC P15056; P61981: YWHAG; NbExp=12; IntAct=EBI-365980, EBI-359832; CC P15056; P27348: YWHAQ; NbExp=12; IntAct=EBI-365980, EBI-359854; CC P15056; P63104: YWHAZ; NbExp=15; IntAct=EBI-365980, EBI-347088; CC P15056; Q61097: Ksr1; Xeno; NbExp=3; IntAct=EBI-365980, EBI-1536336; CC P15056; P29678: MAP2K1; Xeno; NbExp=2; IntAct=EBI-365980, EBI-1631983; CC P15056; Q99N57: Raf1; Xeno; NbExp=3; IntAct=EBI-365980, EBI-397757; CC P15056; Q8CGE9: Rgs12; Xeno; NbExp=2; IntAct=EBI-365980, EBI-7340552; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}. Cytoplasm CC {ECO:0000269|PubMed:19710016}. Cell membrane CC {ECO:0000269|PubMed:19710016}. Note=Colocalizes with RGS14 and RAF1 in CC both the cytoplasm and membranes. {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Brain and testis. CC -!- PTM: Phosphorylation at Ser-365 by SGK1 inhibits its activity (Ref.8, CC PubMed:11410590). Phosphorylation at Thr-753 by MAPK1 CC (PubMed:19710016). Dephosphorylation of Ser-365 by the SHOC2-MRAS-PP1c CC (SMP) complex consisting of SHOC2, GTP-bound M-Ras/MRAS and the CC catalytic subunit of protein phosphatase 1 (PPP1CA, PPP1CB or PPP1CC); CC this relieves inactivation and stimulates kinase activity CC (PubMed:35768504, PubMed:35830882). {ECO:0000269|PubMed:11410590, CC ECO:0000269|PubMed:19710016, ECO:0000269|PubMed:35768504, CC ECO:0000269|PubMed:35830882, ECO:0000269|Ref.8}. CC -!- PTM: Methylation at Arg-671 decreases stability and kinase activity. CC {ECO:0000269|PubMed:21917714}. CC -!- PTM: Ubiquitinated by RNF149; which leads to proteasomal degradation. CC Polyubiquitinated at Lys-578 in response to EGF. CC {ECO:0000269|PubMed:22628551, ECO:0000269|PubMed:23907581}. CC -!- DISEASE: Note=Defects in BRAF are found in a wide range of cancers. CC {ECO:0000269|PubMed:18974108}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:12198537, CC ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:23263490, CC ECO:0000269|PubMed:24455489}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. {ECO:0000269|PubMed:12460919}. Note=The gene represented in CC this entry is involved in disease pathogenesis. CC -!- DISEASE: Familial non-Hodgkin lymphoma (NHL) [MIM:605027]: Cancer that CC starts in cells of the lymph system, which is part of the body's immune CC system. NHLs can occur at any age and are often marked by enlarged CC lymph nodes, fever and weight loss. {ECO:0000269|PubMed:14612909}. CC Note=The gene represented in this entry is involved in disease CC pathogenesis. CC -!- DISEASE: Cardiofaciocutaneous syndrome 1 (CFC1) [MIM:115150]: A CC multiple congenital anomaly disorder characterized by a distinctive CC facial appearance, heart defects and intellectual disability. Heart CC defects include pulmonic stenosis, atrial septal defects and CC hypertrophic cardiomyopathy. Some affected individuals present with CC ectodermal abnormalities such as sparse, friable hair, hyperkeratotic CC skin lesions and a generalized ichthyosis-like condition. Typical CC facial features are similar to Noonan syndrome. They include high CC forehead with bitemporal constriction, hypoplastic supraorbital ridges, CC downslanting palpebral fissures, a depressed nasal bridge, and CC posteriorly angulated ears with prominent helices. CC {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, CC ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Noonan syndrome 7 (NS7) [MIM:613706]: A form of Noonan CC syndrome, a disease characterized by short stature, facial dysmorphic CC features such as hypertelorism, a downward eyeslant and low-set CC posteriorly rotated ears, and a high incidence of congenital heart CC defects and hypertrophic cardiomyopathy. Other features can include a CC short neck with webbing or redundancy of skin, deafness, motor delay, CC variable intellectual deficits, multiple skeletal defects, CC cryptorchidism, and bleeding diathesis. Individuals with Noonan CC syndrome are at risk of juvenile myelomonocytic leukemia, a CC myeloproliferative disorder characterized by excessive production of CC myelomonocytic cells. {ECO:0000269|PubMed:19206169}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- DISEASE: LEOPARD syndrome 3 (LPRD3) [MIM:613707]: A disorder CC characterized by lentigines, electrocardiographic conduction CC abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities CC of genitalia, retardation of growth, and sensorineural deafness. CC {ECO:0000269|PubMed:19206169}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Note=A chromosomal aberration involving BRAF is found in CC pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to CC the expression of a KIAA1549-BRAF fusion protein with a constitutive CC kinase activity and inducing cell transformation. CC {ECO:0000269|PubMed:18974108}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. RAF subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAD43193.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=CAQ43111.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43112.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43113.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43114.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43115.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43116.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/828/BRAF"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M95712; AAA35609.2; -; mRNA. DR EMBL; AC006344; AAD43193.1; ALT_SEQ; Genomic_DNA. DR EMBL; EU600171; ACD11489.1; -; Genomic_DNA. DR EMBL; AC006347; AAD15551.1; -; Genomic_DNA. DR EMBL; CH236950; EAL24023.1; -; Genomic_DNA. DR EMBL; BC101757; AAI01758.1; -; mRNA. DR EMBL; BC112079; AAI12080.1; -; mRNA. DR EMBL; X65187; CAA46301.1; -; Genomic_DNA. DR EMBL; M21001; AAA96495.1; -; mRNA. DR EMBL; AM989472; CAQ43111.1; ALT_INIT; mRNA. DR EMBL; AM989473; CAQ43112.1; ALT_INIT; mRNA. DR EMBL; AM989474; CAQ43113.1; ALT_INIT; mRNA. DR EMBL; AM989475; CAQ43114.1; ALT_INIT; mRNA. DR EMBL; AM989476; CAQ43115.1; ALT_INIT; mRNA. DR EMBL; AM989477; CAQ43116.1; ALT_INIT; mRNA. DR CCDS; CCDS5863.1; -. DR PIR; A57977; TVHUBF. DR RefSeq; NP_004324.2; NM_004333.4. DR PDB; 1UWH; X-ray; 2.95 A; A/B=448-723. DR PDB; 1UWJ; X-ray; 3.50 A; A/B=448-723. DR PDB; 2FB8; X-ray; 2.90 A; A/B=445-723. DR PDB; 2L05; NMR; -; A=149-232. DR PDB; 3C4C; X-ray; 2.57 A; A/B=444-721. DR PDB; 3D4Q; X-ray; 2.80 A; A/B=433-726. DR PDB; 3IDP; X-ray; 2.70 A; A/B=434-727. DR PDB; 3II5; X-ray; 2.79 A; A/B=432-726. DR PDB; 3NY5; X-ray; 1.99 A; A/B/C/D=153-237. DR PDB; 3OG7; X-ray; 2.45 A; A/B=448-720. DR PDB; 3PPJ; X-ray; 3.70 A; A/B=432-726. DR PDB; 3PPK; X-ray; 3.00 A; A/B=432-726. DR PDB; 3PRF; X-ray; 2.90 A; A/B=432-726. DR PDB; 3PRI; X-ray; 3.50 A; A/B=432-726. DR PDB; 3PSB; X-ray; 3.40 A; A/B=433-726. DR PDB; 3PSD; X-ray; 3.60 A; A/B=433-726. DR PDB; 3Q4C; X-ray; 3.20 A; A/B=432-726. DR PDB; 3Q96; X-ray; 3.10 A; A/B=446-727. DR PDB; 3SKC; X-ray; 3.20 A; A/B=432-726. DR PDB; 3TV4; X-ray; 3.40 A; A/B=432-726. DR PDB; 3TV6; X-ray; 3.30 A; A/B=432-726. DR PDB; 4CQE; X-ray; 2.30 A; A/B=448-723. DR PDB; 4DBN; X-ray; 3.15 A; A/B=445-726. DR PDB; 4E26; X-ray; 2.55 A; A/B=432-726. DR PDB; 4E4X; X-ray; 3.60 A; A/B=432-726. DR PDB; 4EHE; X-ray; 3.30 A; A/B=432-726. DR PDB; 4EHG; X-ray; 3.50 A; A/B=432-726. DR PDB; 4FC0; X-ray; 2.95 A; A/B=445-726. DR PDB; 4FK3; X-ray; 2.65 A; A/B=444-723. DR PDB; 4G9C; X-ray; 3.50 A; A/B=432-726. DR PDB; 4G9R; X-ray; 3.20 A; A/B=432-726. DR PDB; 4H58; X-ray; 3.10 A; A/B/C=448-722. DR PDB; 4JVG; X-ray; 3.09 A; A/B/C/D=444-723. DR PDB; 4KSP; X-ray; 2.93 A; A/B=445-726. DR PDB; 4KSQ; X-ray; 3.30 A; A/B=445-726. DR PDB; 4MBJ; X-ray; 3.60 A; A/B=432-723. DR PDB; 4MNE; X-ray; 2.85 A; B/C/F/G=432-726. DR PDB; 4MNF; X-ray; 2.80 A; A/B=432-736. DR PDB; 4PP7; X-ray; 3.40 A; A/B=432-726. DR PDB; 4R5Y; X-ray; 3.50 A; A/B=444-723. DR PDB; 4RZV; X-ray; 2.99 A; A/B=443-723. DR PDB; 4RZW; X-ray; 3.49 A; A/B=443-723. DR PDB; 4WO5; X-ray; 2.83 A; A/B=444-723. DR PDB; 4XV1; X-ray; 2.47 A; A/B=444-705. DR PDB; 4XV2; X-ray; 2.50 A; A/B=444-705. DR PDB; 4XV3; X-ray; 2.80 A; A/B=444-705. DR PDB; 4XV9; X-ray; 2.00 A; A=442-705. DR PDB; 4YHT; X-ray; 3.05 A; A/B=449-720. DR PDB; 5C9C; X-ray; 2.70 A; A/B=432-726. DR PDB; 5CSW; X-ray; 2.66 A; A/B=442-721. DR PDB; 5CSX; X-ray; 2.51 A; A=442-721. DR PDB; 5CT7; X-ray; 3.17 A; A/B=445-723. DR PDB; 5FD2; X-ray; 2.89 A; A/B=433-726. DR PDB; 5HI2; X-ray; 2.51 A; A=444-737. DR PDB; 5HID; X-ray; 2.50 A; A/B=444-737. DR PDB; 5HIE; X-ray; 3.00 A; A/B/C/D=432-726. DR PDB; 5ITA; X-ray; 1.95 A; A/B=448-723. DR PDB; 5J17; NMR; -; A=151-232. DR PDB; 5J18; NMR; -; A=151-232. DR PDB; 5J2R; NMR; -; A=151-232. DR PDB; 5JRQ; X-ray; 2.29 A; A/B=448-723. DR PDB; 5JSM; X-ray; 2.19 A; A/B/C/D=448-723. DR PDB; 5JT2; X-ray; 2.70 A; A/B/C/D=448-723. DR PDB; 5VAL; X-ray; 2.26 A; A/B=445-723. DR PDB; 5VAM; X-ray; 2.10 A; A/B=445-723. DR PDB; 5VR3; X-ray; 2.10 A; A=36-114. DR PDB; 5VYK; X-ray; 1.75 A; A/C=36-110. DR PDB; 6B8U; X-ray; 2.68 A; A/B=445-723. DR PDB; 6CAD; X-ray; 2.55 A; A/B=444-723. DR PDB; 6N0P; X-ray; 2.37 A; A/B=449-721. DR PDB; 6N0Q; X-ray; 2.04 A; A/B=445-723. DR PDB; 6NSQ; X-ray; 3.05 A; A/B=444-723. DR PDB; 6NYB; EM; 4.10 A; A=1-766. DR PDB; 6P3D; X-ray; 2.11 A; A=448-721. DR PDB; 6P7G; X-ray; 2.65 A; A/B/C/D=448-723. DR PDB; 6PP9; X-ray; 2.59 A; A=445-723. DR PDB; 6Q0J; EM; 4.90 A; A/B=1-766. DR PDB; 6Q0K; EM; 6.80 A; A/B=1-766. DR PDB; 6Q0T; EM; 5.70 A; A/B=1-766. DR PDB; 6U2G; X-ray; 2.89 A; B=432-726. DR PDB; 6U2H; X-ray; 2.50 A; C/D=447-735. DR PDB; 6UAN; EM; 3.90 A; B/C=1-766. DR PDB; 6UUO; X-ray; 3.29 A; A/B=444-723. DR PDB; 6V2U; X-ray; 3.78 A; A/B=445-723. DR PDB; 6V2W; X-ray; 3.12 A; A=445-723. DR PDB; 6V34; X-ray; 3.15 A; A/B=448-721. DR PDB; 6XAG; X-ray; 3.30 A; C/D=447-735. DR PDB; 6XFP; X-ray; 2.00 A; A=442-721. DR PDB; 6XLO; X-ray; 2.49 A; A/B=442-721. DR PDB; 7K0V; X-ray; 1.93 A; A/B/C/D=444-723. DR PDB; 7M0T; X-ray; 3.19 A; A=445-723. DR PDB; 7M0U; X-ray; 3.09 A; A=445-723. DR PDB; 7M0V; X-ray; 3.16 A; A=445-723. DR PDB; 7M0W; X-ray; 3.09 A; A=445-723. DR PDB; 7M0X; X-ray; 2.47 A; A=445-723. DR PDB; 7M0Y; X-ray; 3.45 A; A=445-723. DR PDB; 7M0Z; X-ray; 3.12 A; A=445-723. DR PDB; 7MFD; EM; 3.66 A; A=1-766. DR PDB; 7MFE; EM; 4.07 A; A=1-766. DR PDB; 7MFF; EM; 3.89 A; A/B=1-766. DR PDB; 7P3V; X-ray; 2.37 A; A/B=448-719. DR PDB; 7SHV; X-ray; 2.88 A; A/B=432-726. DR PDB; 7ZR0; EM; 3.40 A; K=1-766. DR PDB; 7ZR5; EM; 3.90 A; K=1-766. DR PDB; 7ZR6; EM; 4.20 A; K=1-766. DR PDB; 8C7X; X-ray; 1.65 A; A/B=444-721. DR PDB; 8C7Y; X-ray; 1.65 A; A/B=444-721. DR PDB; 8DGS; EM; 4.30 A; A=1-766. DR PDB; 8DGT; EM; 3.90 A; A=1-766. DR PDB; 8F7O; X-ray; 3.54 A; A/B=441-723. DR PDB; 8F7P; X-ray; 2.74 A; A/B=441-723. DR PDB; 8QQG; X-ray; 2.98 A; A/B/C=448-722. DR PDB; 8VSO; X-ray; 1.50 A; P=361-369. DR PDB; 8VYO; EM; 3.74 A; A=1-766. DR PDB; 8VYP; EM; 3.29 A; C=1-766. DR PDB; 8VYQ; EM; 4.43 A; C=360-734. DR PDB; 8VYR; EM; 4.32 A; A=1-766. DR PDB; 8VYS; EM; 3.06 A; A=1-766. DR PDB; 8VYU; EM; 4.07 A; A=1-766. DR PDB; 8VYV; EM; 5.86 A; C=1-766. DR PDB; 8VYW; EM; 4.76 A; C=360-734. DR PDB; 9AXX; X-ray; 2.07 A; B/D=445-723. DR PDB; 9AXY; X-ray; 3.60 A; A=445-723. DR PDB; 9BFB; X-ray; 1.92 A; A=445-723. DR PDB; 9BP8; X-ray; 1.73 A; A=445-723. DR PDB; 9EW6; X-ray; 1.65 A; P=361-369. DR PDB; 9F35; X-ray; 2.30 A; B=360-370. DR PDBsum; 1UWH; -. DR PDBsum; 1UWJ; -. DR PDBsum; 2FB8; -. DR PDBsum; 2L05; -. DR PDBsum; 3C4C; -. DR PDBsum; 3D4Q; -. DR PDBsum; 3IDP; -. DR PDBsum; 3II5; -. DR PDBsum; 3NY5; -. DR PDBsum; 3OG7; -. DR PDBsum; 3PPJ; -. DR PDBsum; 3PPK; -. DR PDBsum; 3PRF; -. DR PDBsum; 3PRI; -. DR PDBsum; 3PSB; -. DR PDBsum; 3PSD; -. DR PDBsum; 3Q4C; -. DR PDBsum; 3Q96; -. DR PDBsum; 3SKC; -. DR PDBsum; 3TV4; -. DR PDBsum; 3TV6; -. DR PDBsum; 4CQE; -. DR PDBsum; 4DBN; -. DR PDBsum; 4E26; -. DR PDBsum; 4E4X; -. DR PDBsum; 4EHE; -. DR PDBsum; 4EHG; -. DR PDBsum; 4FC0; -. DR PDBsum; 4FK3; -. DR PDBsum; 4G9C; -. DR PDBsum; 4G9R; -. DR PDBsum; 4H58; -. DR PDBsum; 4JVG; -. DR PDBsum; 4KSP; -. DR PDBsum; 4KSQ; -. DR PDBsum; 4MBJ; -. DR PDBsum; 4MNE; -. DR PDBsum; 4MNF; -. DR PDBsum; 4PP7; -. DR PDBsum; 4R5Y; -. DR PDBsum; 4RZV; -. DR PDBsum; 4RZW; -. DR PDBsum; 4WO5; -. DR PDBsum; 4XV1; -. DR PDBsum; 4XV2; -. DR PDBsum; 4XV3; -. DR PDBsum; 4XV9; -. DR PDBsum; 4YHT; -. DR PDBsum; 5C9C; -. DR PDBsum; 5CSW; -. DR PDBsum; 5CSX; -. DR PDBsum; 5CT7; -. DR PDBsum; 5FD2; -. DR PDBsum; 5HI2; -. DR PDBsum; 5HID; -. DR PDBsum; 5HIE; -. DR PDBsum; 5ITA; -. DR PDBsum; 5J17; -. DR PDBsum; 5J18; -. DR PDBsum; 5J2R; -. DR PDBsum; 5JRQ; -. DR PDBsum; 5JSM; -. DR PDBsum; 5JT2; -. DR PDBsum; 5VAL; -. DR PDBsum; 5VAM; -. DR PDBsum; 5VR3; -. DR PDBsum; 5VYK; -. DR PDBsum; 6B8U; -. DR PDBsum; 6CAD; -. DR PDBsum; 6N0P; -. DR PDBsum; 6N0Q; -. DR PDBsum; 6NSQ; -. DR PDBsum; 6NYB; -. DR PDBsum; 6P3D; -. DR PDBsum; 6P7G; -. DR PDBsum; 6PP9; -. DR PDBsum; 6Q0J; -. DR PDBsum; 6Q0K; -. DR PDBsum; 6Q0T; -. DR PDBsum; 6U2G; -. DR PDBsum; 6U2H; -. DR PDBsum; 6UAN; -. DR PDBsum; 6UUO; -. DR PDBsum; 6V2U; -. DR PDBsum; 6V2W; -. DR PDBsum; 6V34; -. DR PDBsum; 6XAG; -. DR PDBsum; 6XFP; -. DR PDBsum; 6XLO; -. DR PDBsum; 7K0V; -. DR PDBsum; 7M0T; -. DR PDBsum; 7M0U; -. DR PDBsum; 7M0V; -. DR PDBsum; 7M0W; -. DR PDBsum; 7M0X; -. DR PDBsum; 7M0Y; -. DR PDBsum; 7M0Z; -. DR PDBsum; 7MFD; -. DR PDBsum; 7MFE; -. DR PDBsum; 7MFF; -. DR PDBsum; 7P3V; -. DR PDBsum; 7SHV; -. DR PDBsum; 7ZR0; -. DR PDBsum; 7ZR5; -. DR PDBsum; 7ZR6; -. DR PDBsum; 8C7X; -. DR PDBsum; 8C7Y; -. DR PDBsum; 8DGS; -. DR PDBsum; 8DGT; -. DR PDBsum; 8F7O; -. DR PDBsum; 8F7P; -. DR PDBsum; 8QQG; -. DR PDBsum; 8VSO; -. DR PDBsum; 8VYO; -. DR PDBsum; 8VYP; -. DR PDBsum; 8VYQ; -. DR PDBsum; 8VYR; -. DR PDBsum; 8VYS; -. DR PDBsum; 8VYU; -. DR PDBsum; 8VYV; -. DR PDBsum; 8VYW; -. DR PDBsum; 9AXX; -. DR PDBsum; 9AXY; -. DR PDBsum; 9BFB; -. DR PDBsum; 9BP8; -. DR PDBsum; 9EW6; -. DR PDBsum; 9F35; -. DR AlphaFoldDB; P15056; -. DR BMRB; P15056; -. DR EMDB; EMD-0541; -. DR EMDB; EMD-14875; -. DR EMDB; EMD-14883; -. DR EMDB; EMD-14884; -. DR EMDB; EMD-20550; -. DR EMDB; EMD-20551; -. DR EMDB; EMD-20552; -. DR EMDB; EMD-20708; -. DR EMDB; EMD-23813; -. DR EMDB; EMD-23814; -. DR EMDB; EMD-23815; -. DR EMDB; EMD-27428; -. DR EMDB; EMD-27429; -. DR EMDB; EMD-43673; -. DR EMDB; EMD-43674; -. DR EMDB; EMD-43675; -. DR EMDB; EMD-43676; -. DR EMDB; EMD-43677; -. DR EMDB; EMD-43678; -. DR EMDB; EMD-43679; -. DR EMDB; EMD-43680; -. DR SMR; P15056; -. DR BioGRID; 107141; 185. DR CORUM; P15056; -. DR DIP; DIP-1045N; -. DR FunCoup; P15056; 5390. DR IntAct; P15056; 446. DR MINT; P15056; -. DR STRING; 9606.ENSP00000419060; -. DR BindingDB; P15056; -. DR ChEMBL; CHEMBL5145; -. DR DrugBank; DB08553; (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime. DR DrugBank; DB15068; Agerafenib. DR DrugBank; DB15254; Avutometinib. DR DrugBank; DB12854; BMS-908662. DR DrugBank; DB08912; Dabrafenib. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB14773; Lifirafenib. DR DrugBank; DB07000; N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide. DR DrugBank; DB06999; PLX-4720. DR DrugBank; DB16038; PLX8394. DR DrugBank; DB05984; RAF-265. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB14840; Ripretinib. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB15266; Tovorafenib. DR DrugBank; DB08881; Vemurafenib. DR DrugBank; DB05190; XL281. DR DrugCentral; P15056; -. DR GuidetoPHARMACOLOGY; 1943; -. DR TCDB; 8.A.23.1.48; the basigin (basigin) family. DR GlyGen; P15056; 1 site. DR iPTMnet; P15056; -. DR PhosphoSitePlus; P15056; -. DR SwissPalm; P15056; -. DR BioMuta; BRAF; -. DR DMDM; 50403720; -. DR CPTAC; CPTAC-3112; -. DR CPTAC; CPTAC-3113; -. DR CPTAC; CPTAC-5771; -. DR CPTAC; CPTAC-5817; -. DR CPTAC; CPTAC-5818; -. DR CPTAC; CPTAC-5819; -. DR CPTAC; CPTAC-5820; -. DR CPTAC; CPTAC-5821; -. DR CPTAC; CPTAC-5822; -. DR CPTAC; non-CPTAC-5352; -. DR CPTAC; non-CPTAC-5353; -. DR CPTAC; non-CPTAC-5354; -. DR CPTAC; non-CPTAC-5355; -. DR CPTAC; non-CPTAC-5356; -. DR CPTAC; non-CPTAC-5357; -. DR CPTAC; non-CPTAC-5727; -. DR CPTAC; non-CPTAC-5728; -. DR CPTAC; non-CPTAC-5729; -. DR jPOST; P15056; -. DR MassIVE; P15056; -. DR PaxDb; 9606-ENSP00000288602; -. DR PeptideAtlas; P15056; -. DR ProteomicsDB; 53102; -. DR Pumba; P15056; -. DR Antibodypedia; 751; 2321 antibodies from 54 providers. DR CPTC; P15056; 7 antibodies. DR DNASU; 673; -. DR Ensembl; ENST00000646891.2; ENSP00000493543.1; ENSG00000157764.15. DR GeneID; 673; -. DR KEGG; hsa:673; -. DR MANE-Select; ENST00000646891.2; ENSP00000493543.1; NM_004333.6; NP_004324.2. DR UCSC; uc003vwc.5; human. DR AGR; HGNC:1097; -. DR CIViC; 673; 6 clinical assertions and 454 evidence items across 166 molecular profiles. DR ClinPGx; PA25408; -. DR CTD; 673; -. DR DisGeNET; 673; -. DR GeneCards; BRAF; -. DR GeneReviews; BRAF; -. DR HGNC; HGNC:1097; BRAF. DR HPA; ENSG00000157764; Low tissue specificity. DR MalaCards; BRAF; -. DR MIM; 114500; phenotype. DR MIM; 115150; phenotype. DR MIM; 164757; gene. DR MIM; 211980; phenotype. DR MIM; 605027; phenotype. DR MIM; 613706; phenotype. DR MIM; 613707; phenotype. DR OpenTargets; ENSG00000157764; -. DR Orphanet; 1340; Cardiofaciocutaneous syndrome. DR Orphanet; 58017; Classic hairy cell leukemia. DR Orphanet; 54595; Craniopharyngioma. DR Orphanet; 96253; Cushing disease. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 389; Langerhans cell histiocytosis. DR Orphanet; 626; Large/giant congenital melanocytic nevus. DR Orphanet; 648; Noonan syndrome. DR Orphanet; 500; Noonan syndrome with multiple lentigines. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR Orphanet; 840; Syringocystadenoma papilliferum. DR VEuPathDB; HostDB:ENSG00000157764; -. DR eggNOG; KOG0193; Eukaryota. DR GeneTree; ENSGT00940000156154; -. DR HOGENOM; CLU_023684_1_0_1; -. DR InParanoid; P15056; -. DR OrthoDB; 774951at2759; -. DR PAN-GO; P15056; 3 GO annotations based on evolutionary models. DR PhylomeDB; P15056; -. DR BRENDA; 2.7.10.2; 2681. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P15056; -. DR Reactome; R-HSA-1295596; Spry regulation of FGF signaling. DR Reactome; R-HSA-170968; Frs2-mediated activation. DR Reactome; R-HSA-170984; ARMS-mediated activation. DR Reactome; R-HSA-187706; Signalling to p38 via RIT and RIN. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-5674499; Negative feedback regulation of MAPK pathway. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR Reactome; R-HSA-9726840; SHOC2 M1731 mutant abolishes MRAS complex function. DR Reactome; R-HSA-9726842; Gain-of-function MRAS complexes activate RAF signaling. DR SignaLink; P15056; -. DR SIGNOR; P15056; -. DR Agora; ENSG00000157764; -. DR BioGRID-ORCS; 673; 88 hits in 1213 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; D57F7ABA; Synthetic Condensate 000274. DR ChiTaRS; BRAF; human. DR EvolutionaryTrace; P15056; -. DR GeneWiki; BRAF_(gene); -. DR GenomeRNAi; 673; -. DR Pharos; P15056; Tclin. DR PRO; PR:P15056; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; P15056; protein. DR Bgee; ENSG00000157764; Expressed in buccal mucosa cell and 183 other cell types or tissues. DR ExpressionAtlas; P15056; baseline and differential. DR GO; GO:0044297; C:cell body; IEA:Ensembl. DR GO; GO:0034451; C:centriolar satellite; IDA:HPA. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005739; C:mitochondrion; IBA:GO_Central. DR GO; GO:0043005; C:neuron projection; IEA:Ensembl. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0098794; C:postsynapse; IEA:GOC. DR GO; GO:0098793; C:presynapse; IEA:GOC. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004708; F:MAP kinase kinase activity; IMP:UniProtKB. DR GO; GO:0004709; F:MAP kinase kinase kinase activity; IBA:GO_Central. DR GO; GO:0004672; F:protein kinase activity; IDA:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0009887; P:animal organ morphogenesis; TAS:ProtInc. DR GO; GO:0043369; P:CD4-positive or CD8-positive, alpha-beta T cell lineage commitment; IEA:Ensembl. DR GO; GO:0043367; P:CD4-positive, alpha-beta T cell differentiation; IEA:Ensembl. DR GO; GO:0071277; P:cellular response to calcium ion; IDA:BHF-UCL. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0072577; P:endothelial cell apoptotic process; IEA:Ensembl. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0070371; P:ERK1 and ERK2 cascade; IBA:GO_Central. DR GO; GO:0090150; P:establishment of protein localization to membrane; IDA:CACAO. DR GO; GO:0060324; P:face development; IEA:Ensembl. DR GO; GO:0060323; P:head morphogenesis; IEA:Ensembl. DR GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IDA:UniProtKB. DR GO; GO:0002318; P:myeloid progenitor cell differentiation; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IEA:Ensembl. DR GO; GO:0010764; P:negative regulation of fibroblast migration; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:2000301; P:negative regulation of synaptic vesicle exocytosis; IEA:Ensembl. DR GO; GO:0048680; P:positive regulation of axon regeneration; IEA:Ensembl. DR GO; GO:0050772; P:positive regulation of axonogenesis; IEA:Ensembl. DR GO; GO:0010828; P:positive regulation of D-glucose transmembrane transport; IDA:CACAO. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0051496; P:positive regulation of stress fiber assembly; IEA:Ensembl. DR GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; IEA:Ensembl. DR GO; GO:0099170; P:postsynaptic modulation of chemical synaptic transmission; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0042127; P:regulation of cell population proliferation; IEA:Ensembl. DR GO; GO:0045580; P:regulation of T cell differentiation; IEA:Ensembl. DR GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl. DR GO; GO:0043149; P:stress fiber assembly; IEA:Ensembl. DR GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl. DR GO; GO:0016079; P:synaptic vesicle exocytosis; IEA:Ensembl. DR GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl. DR GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0030878; P:thyroid gland development; IEA:Ensembl. DR GO; GO:0008542; P:visual learning; IEA:Ensembl. DR CDD; cd20871; C1_B-Raf; 1. DR CDD; cd17134; RBD_BRAF; 1. DR CDD; cd14062; STKc_Raf; 1. DR DisProt; DP03825; -. DR FunFam; 3.10.20.90:FF:000015; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000024; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.60.20:FF:000004; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 1.10.510.10:FF:000036; RAF proto-oncogene serine/threonine-protein kinase; 1. DR Gene3D; 3.30.60.20; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR003116; RBD_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR PANTHER; PTHR44329:SF240; SERINE_THREONINE-PROTEIN KINASE B-RAF; 1. DR Pfam; PF00130; C1_1; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF02196; RBD; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 1. DR SMART; SM00455; RBD; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50898; RBD; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 1. DR PROSITE; PS50081; ZF_DAG_PE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Allosteric enzyme; ATP-binding; Cardiomyopathy; KW Cell membrane; Chromosomal rearrangement; Cytoplasm; Deafness; KW Direct protein sequencing; Disease variant; Ectodermal dysplasia; KW Intellectual disability; Isopeptide bond; Kinase; Membrane; Metal-binding; KW Methylation; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation; Zinc; KW Zinc-finger. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.8" FT CHAIN 2..766 FT /note="Serine/threonine-protein kinase B-raf" FT /id="PRO_0000085665" FT DOMAIN 155..227 FT /note="RBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00262" FT DOMAIN 457..717 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 234..280 FT /note="Phorbol-ester/DAG-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 1..38 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 308..454 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..13 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 314..341 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 348..363 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 423..447 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 576 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 235 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 248 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 251 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 261 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 264 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 269 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 272 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 280 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 463..471 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 483 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 380..381 FT /note="Breakpoint for translocation to form KIAA1549-BRAF FT fusion protein" FT SITE 438..439 FT /note="Breakpoint for translocation to form KIAA1549-BRAF FT fusion protein" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 151 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 333 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P28028" FT MOD_RES 365 FT /note="Phosphoserine; by SGK1" FT /evidence="ECO:0000269|PubMed:11410590, ECO:0000269|Ref.8, FT ECO:0007744|PubMed:23186163" FT MOD_RES 373 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:1508179" FT MOD_RES 396 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 399 FT /note="Phosphoserine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 401 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 446 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 447 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 671 FT /note="Omega-N-methylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:21917714" FT MOD_RES 729 FT /note="Phosphoserine" FT /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 750 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P28028" FT MOD_RES 753 FT /note="Phosphothreonine; by MAPK1" FT /evidence="ECO:0000269|PubMed:19710016" FT CROSSLNK 578 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:23907581" FT VARIANT 241 FT /note="T -> M (in NS7; dbSNP:rs387906660)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058620" FT VARIANT 241 FT /note="T -> P (in CFC1 and LPRD3; dbSNP:rs387906661)" FT /evidence="ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_058621" FT VARIANT 241 FT /note="T -> R (in NS7; dbSNP:rs387906660)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058622" FT VARIANT 244 FT /note="T -> P (in CFC1; dbSNP:rs397507465)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065171" FT VARIANT 245 FT /note="L -> F (in CFC1; dbSNP:rs397507466)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058623" FT VARIANT 246 FT /note="A -> P (in CFC1; dbSNP:rs180177034)" FT /evidence="ECO:0000269|PubMed:16474404, FT ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169" FT /id="VAR_026113" FT VARIANT 257 FT /note="Q -> R (in CFC1; dbSNP:rs180177035)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_026114" FT VARIANT 262 FT /note="Q -> K (in CFC1; dbSNP:rs397507470)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065172" FT VARIANT 275 FT /note="E -> K (in CFC1; dbSNP:rs2129044284)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058624" FT VARIANT 301 FT /note="P -> S (in dbSNP:rs34776339)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040391" FT VARIANT 462 FT /note="R -> I (in CRC; dbSNP:rs180177032)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018613" FT VARIANT 463 FT /note="I -> S (in CRC; dbSNP:rs180177033)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018614" FT VARIANT 464 FT /note="G -> E (in CRC; dbSNP:rs121913348)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12198537" FT /id="VAR_018615" FT VARIANT 464 FT /note="G -> V (in a colorectal cancer cell line; elevated FT kinase activity; efficiently induces cell transformation; FT dbSNP:rs121913348)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018616" FT VARIANT 466 FT /note="G -> A (in melanoma; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018617" FT VARIANT 466 FT /note="G -> E (in melanoma; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018618" FT VARIANT 466 FT /note="G -> V (in LNCR; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12460919" FT /id="VAR_018512" FT VARIANT 467 FT /note="S -> A (in CFC1; dbSNP:rs869025606)" FT /evidence="ECO:0000269|PubMed:16439621" FT /id="VAR_035096" FT VARIANT 468 FT /note="F -> S (in CFC1; dbSNP:rs397507473)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:18042262" FT /id="VAR_035097" FT VARIANT 469 FT /note="G -> A (in NHL; also in a lung adenocarcinoma FT sample; somatic mutation; elevated kinase activity; FT efficiently induces cell transformation; FT dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:14612909, ECO:0000269|PubMed:17344846" FT /id="VAR_018620" FT VARIANT 469 FT /note="G -> E (in CFC1 and colon cancer; FT dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, FT ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169" FT /id="VAR_018621" FT VARIANT 469 FT /note="G -> R (in NHL; dbSNP:rs121913357)" FT /evidence="ECO:0000269|PubMed:14612909" FT /id="VAR_018622" FT VARIANT 469 FT /note="G -> V (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040392" FT VARIANT 485 FT /note="L -> F (in CFC1; dbSNP:rs180177036)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:19206169" FT /id="VAR_026115" FT VARIANT 499 FT /note="K -> E (in CFC1; dbSNP:rs180177037)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262" FT /id="VAR_026116" FT VARIANT 499 FT /note="K -> N (in CFC1; dbSNP:rs397507476)" FT /evidence="ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_058625" FT VARIANT 501 FT /note="E -> G (in CFC1; dbSNP:rs180177039)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404" FT /id="VAR_026117" FT VARIANT 501 FT /note="E -> K (in CFC1; dbSNP:rs180177038)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:19206169" FT /id="VAR_026118" FT VARIANT 525 FT /note="L -> P (in CFC1; dbSNP:rs869025340)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058626" FT VARIANT 531 FT /note="W -> C (in NS7; dbSNP:rs606231228)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058627" FT VARIANT 580 FT /note="N -> D (in CFC1; dbSNP:rs2128999571)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065173" FT VARIANT 581 FT /note="N -> D (in CFC1; dbSNP:rs180177040)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262" FT /id="VAR_026119" FT VARIANT 581 FT /note="N -> S (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913370)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040393" FT VARIANT 586 FT /note="E -> K (in ovarian cancer; dbSNP:rs121913340)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018623" FT VARIANT 594 FT /note="D -> G (in NHL; dbSNP:rs121913338)" FT /evidence="ECO:0000269|PubMed:14612909" FT /id="VAR_018624" FT VARIANT 595 FT /note="F -> L (in CFC1; also found in colon cancer; FT dbSNP:rs121913341)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_018625" FT VARIANT 596 FT /note="G -> R (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913361)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:17344846" FT /id="VAR_018626" FT VARIANT 596 FT /note="G -> V (in CFC1; dbSNP:rs397507483)" FT /evidence="ECO:0000269|PubMed:16439621" FT /id="VAR_035098" FT VARIANT 597 FT /note="L -> R (in LNCR; also found in an ovarian serous FT carcinoma sample; somatic mutation; dbSNP:rs121913366)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12460919, ECO:0000269|PubMed:17344846" FT /id="VAR_018513" FT VARIANT 597 FT /note="L -> V (in NS7; also in a lung adenocarcinoma FT sample; somatic mutation; elevated kinase activity; FT efficiently induces cell transformation; FT dbSNP:rs121913369)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19206169" FT /id="VAR_018627" FT VARIANT 599 FT /note="T -> R (in CFC1; dbSNP:rs121913375)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058628" FT VARIANT 600 FT /note="V -> D (in a melanoma cell line; requires 2 FT nucleotide substitutions; dbSNP:rs121913377)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018628" FT VARIANT 600 FT /note="V -> E (in CRC; also found in sarcoma, metastatic FT melanoma, ovarian serous carcinoma, pilocytic astrocytoma; FT somatic mutation; most common mutation; constitutive and FT elevated kinase activity; efficiently induces cell FT transformation; suppression of mutation in melanoma causes FT growth arrest and promotes apoptosis; loss of regulation by FT PMRT5; dbSNP:rs113488022)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12198537, ECO:0000269|PubMed:14500344, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:23263490, FT ECO:0000269|PubMed:24455489" FT /id="VAR_018629" FT VARIANT 601 FT /note="K -> E (in CRC; dbSNP:rs121913364)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018630" FT VARIANT 601 FT /note="K -> Q (in CFC1; dbSNP:rs121913364)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058629" FT VARIANT 638 FT /note="D -> E (in CFC1; dbSNP:rs180177042)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058630" FT VARIANT 709 FT /note="Q -> R (in CFC1; dbSNP:rs397507486)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058631" FT MUTAGEN 53 FT /note="M->D: Reduces interaction with KSR1 and MAP2K1 and FT thus phosphorylation of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 88 FT /note="K->E: Reduces interaction with KSR1 and MAP2K1 and FT thus phosphorylation of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 483 FT /note="K->S: Reduces kinase activity with MAP2K1." FT /evidence="ECO:0000269|PubMed:21441910" FT MUTAGEN 509 FT /note="R->H: Loss of MAP2K1-mediated-BRAF-KSR1 FT dimerization." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 578 FT /note="K->R: Blocks EGF-induced ubiquitination and ERK FT activation." FT /evidence="ECO:0000269|PubMed:23907581" FT MUTAGEN 666 FT /note="I->R: No effect on MAP2K1-mediated-BRAF-KSR1 FT dimerization, however loss of BRAF-mediated phosphorylation FT of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 671 FT /note="R->K: Increased kinase activity and stability in FT response to EGF treatment." FT /evidence="ECO:0000269|PubMed:21917714" FT CONFLICT 766 FT /note="H -> D (in Ref. 11; AAA96495)" FT /evidence="ECO:0000305" FT HELIX 43..68 FT /evidence="ECO:0007829|PDB:5VYK" FT HELIX 76..103 FT /evidence="ECO:0007829|PDB:5VYK" FT STRAND 156..161 FT /evidence="ECO:0007829|PDB:3NY5" FT TURN 162..164 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 165..170 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 177..186 FT /evidence="ECO:0007829|PDB:3NY5" FT TURN 187..189 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 192..194 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 195..199 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 206..208 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 214..217 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 221..226 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 448..450 FT /evidence="ECO:0007829|PDB:6P3D" FT HELIX 454..456 FT /evidence="ECO:0007829|PDB:5JRQ" FT STRAND 458..466 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 469..484 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 487..489 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 492..505 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 516..520 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 522..524 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 526..530 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 534..536 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 537..542 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 543..545 FT /evidence="ECO:0007829|PDB:6P3D" FT HELIX 550..569 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 579..581 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 582..585 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 586..588 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 589..592 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 598..600 FT /evidence="ECO:0007829|PDB:6XFP" FT TURN 602..605 FT /evidence="ECO:0007829|PDB:4RZV" FT HELIX 609..612 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 614..619 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 622..626 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 629..631 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 635..651 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 655..658 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 662..671 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 678..680 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 683..685 FT /evidence="ECO:0007829|PDB:5JRQ" FT HELIX 687..696 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 701..703 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 707..721 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 723..726 FT /evidence="ECO:0007829|PDB:6U2H" SQ SEQUENCE 766 AA; 84437 MW; 0798C2AAB487E813 CRC64; MAALSGGGGG GAEPGQALFN GDMEPEAGAG AGAAASSAAD PAIPEEVWNI KQMIKLTQEH IEALLDKFGG EHNPPSIYLE AYEEYTSKLD ALQQREQQLL ESLGNGTDFS VSSSASMDTV TSSSSSSLSV LPSSLSVFQN PTDVARSNPK SPQKPIVRVF LPNKQRTVVP ARCGVTVRDS LKKALMMRGL IPECCAVYRI QDGEKKPIGW DTDISWLTGE ELHVEVLENV PLTTHNFVRK TFFTLAFCDF CRKLLFQGFR CQTCGYKFHQ RCSTEVPLMC VNYDQLDLLF VSKFFEHHPI PQEEASLAET ALTSGSSPSA PASDSIGPQI LTSPSPSKSI PIPQPFRPAD EDHRNQFGQR DRSSSAPNVH INTIEPVNID DLIRDQGFRG DGGSTTGLSA TPPASLPGSL TNVKALQKSP GPQRERKSSS SSEDRNRMKT LGRRDSSDDW EIPDGQITVG QRIGSGSFGT VYKGKWHGDV AVKMLNVTAP TPQQLQAFKN EVGVLRKTRH VNILLFMGYS TKPQLAIVTQ WCEGSSLYHH LHIIETKFEM IKLIDIARQT AQGMDYLHAK SIIHRDLKSN NIFLHEDLTV KIGDFGLATV KSRWSGSHQF EQLSGSILWM APEVIRMQDK NPYSFQSDVY AFGIVLYELM TGQLPYSNIN NRDQIIFMVG RGYLSPDLSK VRSNCPKAMK RLMAECLKKK RDERPLFPQI LASIELLARS LPKIHRSASE PSLNRAGFQT EDFSLYACAS PKTPIQAGGY GAFPVH // ID CASPA_HUMAN Reviewed; 521 AA. AC Q92851; Q68HC0; Q6KF62; Q6KF63; Q8IUP5; Q8WYQ8; Q99845; Q9Y2U6; Q9Y2U7; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2001, sequence version 3. DT 28-JAN-2026, entry version 241. DE RecName: Full=Caspase-10; DE Short=CASP-10; DE EC=3.4.22.63 {ECO:0000269|PubMed:16916640}; DE AltName: Full=Apoptotic protease Mch-4; DE AltName: Full=FAS-associated death domain protein interleukin-1B-converting enzyme 2; DE Short=FLICE2; DE AltName: Full=ICE-like apoptotic protease 4; DE Contains: DE RecName: Full=Caspase-10 subunit p23/17; DE Contains: DE RecName: Full=Caspase-10 subunit p12; DE Flags: Precursor; GN Name=CASP10; Synonyms=MCH4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B), AND VARIANT ILE-479 (ISOFORM B). RC TISSUE=T-cell; RX PubMed=8755496; DOI=10.1073/pnas.93.15.7464; RA Fernandes-Alnemri T., Armstrong R.C., Krebs J.F., Srinivasula S.M., RA Wang L., Bullrich F., Fritz L.C., Trapani J.A., Tomaselli K.J., Litwack G., RA Alnemri E.S.; RT "In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic RT cysteine protease containing two FADD-like domains."; RL Proc. Natl. Acad. Sci. U.S.A. 93:7464-7469(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A). RX PubMed=9045686; DOI=10.1074/jbc.272.10.6578; RA Vincenz C., Dixit V.M.; RT "Fas-associated death domain protein interleukin-1beta-converting enzyme 2 RT (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95- and p55- RT mediated death signaling."; RL J. Biol. Chem. 272:6578-6583(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS C AND D), VARIANT ILE-410, AND VARIANT RP ILE-522 (ISOFORM D). RC TISSUE=Spleen, and Thymus; RX PubMed=10187817; DOI=10.1074/jbc.274.15.10301; RA Ng P.W., Porter A.G., Janicke R.U.; RT "Molecular cloning and characterization of two novel pro-apoptotic isoforms RT of caspase-10."; RL J. Biol. Chem. 274:10301-10308(1999). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORMS A AND B), RP AND VARIANT ILE-479 (ISOFORM B). RX PubMed=11161814; DOI=10.1006/geno.2000.6392; RA Hadano S., Yanagisawa Y., Skaug J., Fichter K., Nasir J., Martindale D., RA Koop B.F., Scherer S.W., Nicholson D.W., Rouleau G.A., Ikeda J.-E., RA Hayden M.R.; RT "Cloning and characterization of three novel genes, ALS2CR1, ALS2CR2, and RT ALS2CR3, in the juvenile amyotrophic lateral sclerosis (ALS2) critical RT region at chromosome 2q33-q34: candidate genes for ALS2."; RL Genomics 71:200-213(2001). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5 AND 6), AND VARIANT ILE-455 (ISOFORM RP 6). RC TISSUE=Blood; RA Vonarbourg C., Fischer A., Rieux-Laucat F.; RT "A novel human caspase 10 isoform participating in Fas-induced apoptosis."; RL Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 7), AND FUNCTION (ISOFORM 7). RX PubMed=17822854; DOI=10.1016/j.bbagen.2007.07.010; RA Wang H., Wang P., Sun X., Luo Y., Wang X., Ma D., Wu J.; RT "Cloning and characterization of a novel caspase-10 isoform that activates RT NF-kappa B activity."; RL Biochim. Biophys. Acta 1770:1528-1537(2007). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-239; ILE-410; SER-444; RP CYS-446 AND ILE-522 (ISOFORM 2). RG NIEHS SNPs program; RL Submitted (OCT-2006) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM D). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP PARTIAL PROTEIN SEQUENCE, AND PROTEOLYTIC PROCESSING. RX PubMed=8962078; DOI=10.1073/pnas.93.25.14486; RA Srinivasula S.M., Ahmad M., Fernandes-Alnemri T., Litwack G., Alnemri E.S.; RT "Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease RT Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like RT cysteine proteases."; RL Proc. Natl. Acad. Sci. U.S.A. 93:14486-14491(1996). RN [12] RP FUNCTION, SELF-ASSOCIATION, INTERACTION WITH FADD, INTERACTION WITH CASP8, RP IDENTIFICATION IN A COMPLEX WITH FAS; FADD AND CASP8, AND MUTAGENESIS OF RP CYS-401. RX PubMed=11717445; DOI=10.1073/pnas.241358198; RA Wang J., Chun H.J., Wong W., Spencer D.M., Lenardo M.J.; RT "Caspase-10 is an initiator caspase in death receptor signaling."; RL Proc. Natl. Acad. Sci. U.S.A. 98:13884-13888(2001). RN [13] RP SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S). RX PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8; RA Hillman R.T., Green R.E., Brenner S.E.; RT "An unappreciated role for RNA surveillance."; RL Genome Biol. 5:R8.1-R8.16(2004). RN [14] RP INTERACTION WITH RFFL AND RNF34. RX PubMed=15069192; DOI=10.1073/pnas.0307459101; RA McDonald E.R. III, El-Deiry W.S.; RT "Suppression of caspase-8- and -10-associated RING proteins results in RT sensitization to death ligands and inhibition of tumor cell growth."; RL Proc. Natl. Acad. Sci. U.S.A. 101:6170-6175(2004). RN [15] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=16916640; DOI=10.1016/j.molcel.2006.06.020; RA Denault J.B., Bekes M., Scott F.L., Sexton K.M., Bogyo M., Salvesen G.S.; RT "Engineered hybrid dimers: tracking the activation pathway of caspase-7."; RL Mol. Cell 23:523-533(2006). RN [16] RP INTERACTION WITH RIOK3. RX PubMed=19557502; DOI=10.1007/s11010-009-0180-8; RA Shan J., Wang P., Zhou J., Wu D., Shi H., Huo K.; RT "RIOK3 interacts with caspase-10 and negatively regulates the NF-kappaB RT signaling pathway."; RL Mol. Cell. Biochem. 332:113-120(2009). RN [17] RP VARIANT ALPS2A PHE-285, VARIANT ILE-410, AND ALTERNATIVE SPLICING (ISOFORMS RP B AND D). RX PubMed=10412980; DOI=10.1016/s0092-8674(00)80605-4; RA Wang J., Zheng L., Lobito A., Chan F.K., Dale J., Sneller M., Yao X., RA Puck J.M., Straus S.E., Lenardo M.J.; RT "Inherited human caspase 10 mutations underlie defective lymphocyte and RT dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type RT II."; RL Cell 98:47-58(1999). RN [18] RP VARIANT NHL VAL-414. RX PubMed=12010812; DOI=10.1182/blood.v99.11.4094; RA Shin M.S., Kim H.S., Kang C.S., Park W.S., Kim S.Y., Lee S.N., Lee J.H., RA Park J.Y., Jang J.J., Kim C.W., Kim S.H., Lee J.Y., Yoo N.J., Lee S.H.; RT "Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas."; RL Blood 99:4094-4099(2002). RN [19] RP VARIANT GASC THR-147, AND CHARACTERIZATION OF VARIANT GASC THR-147. RX PubMed=11973654; DOI=10.1038/sj.onc.1205394; RA Park W.S., Lee J.H., Shin M.S., Park J.Y., Kim H.S., Lee J.H., Kim Y.S., RA Lee S.N., Xiao W., Park C.H., Lee S.H., Yoo N.J., Lee J.Y.; RT "Inactivating mutations of the caspase-10 gene in gastric cancer."; RL Oncogene 21:2919-2925(2002). RN [20] RP VARIANTS LEU-406; ILE-410 AND CYS-446, AND CHARACTERIZATION OF VARIANTS RP LEU-406; ILE-410 AND CYS-446. RX PubMed=16446975; DOI=10.1007/s00439-006-0138-9; RA Zhu S., Hsu A.P., Vacek M.M., Zheng L., Schaeffer A.A., Dale J.K., RA Davis J., Fischer R.E., Straus S.E., Boruchov D., Saulsbury F.T., RA Lenardo M.J., Puck J.M.; RT "Genetic alterations in caspase-10 may be causative or protective in RT autoimmune lymphoproliferative syndrome."; RL Hum. Genet. 119:284-294(2006). RN [21] RP VARIANT ILE-522 (ISOFORM D), AND RISK FACTOR FOR CUTANEOUS MELANOMA. RX PubMed=18563783; DOI=10.1002/humu.20803; RA Li C., Zhao H., Hu Z., Liu Z., Wang L.-E., Gershenwald J.E., Prieto V.G., RA Lee J.E., Duvic M., Grimm E.A., Wei Q.; RT "Genetic variants and haplotypes of the caspase-8 and caspase-10 genes RT contribute to susceptibility to cutaneous melanoma."; RL Hum. Mutat. 29:1443-1451(2008). RN [22] RP VARIANTS CYS-21 AND PRO-285. RX PubMed=19900088; DOI=10.1080/00313020903041143; RA Kim M.S., Oh J.E., Min C.K., Lee S., Chung N.G., Yoo N.J., Lee S.H.; RT "Mutational analysis of CASP10 gene in acute leukaemias and multiple RT myelomas."; RL Pathology 41:484-487(2009). RN [23] RP VARIANT THR-14. RX PubMed=20025484; DOI=10.3109/00313020903434371; RA Oh J.E., Kim M.S., Ahn C.H., Kim S.S., Han J.Y., Lee S.H., Yoo N.J.; RT "Mutational analysis of CASP10 gene in colon, breast, lung and RT hepatocellular carcinomas."; RL Pathology 42:73-76(2010). RN [24] RP VARIANT LEU-406. RX PubMed=27378136; DOI=10.1016/j.imlet.2016.07.001; RA Tripodi S.I., Mazza C., Moratto D., Ramenghi U., Caorsi R., Gattorno M., RA Badolato R.; RT "Atypical presentation of autoimmune lymphoproliferative syndrome due to RT CASP10 mutation."; RL Immunol. Lett. 177:22-24(2016). RN [25] RP VARIANT LEU-406. RX PubMed=27535533; DOI=10.1038/nature19057; RG Exome Aggregation Consortium; RA Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E., Fennell T., RA O'Donnell-Luria A.H., Ware J.S., Hill A.J., Cummings B.B., Tukiainen T., RA Birnbaum D.P., Kosmicki J.A., Duncan L.E., Estrada K., Zhao F., Zou J., RA Pierce-Hoffman E., Berghout J., Cooper D.N., Deflaux N., DePristo M., RA Do R., Flannick J., Fromer M., Gauthier L., Goldstein J., Gupta N., RA Howrigan D., Kiezun A., Kurki M.I., Moonshine A.L., Natarajan P., RA Orozco L., Peloso G.M., Poplin R., Rivas M.A., Ruano-Rubio V., Rose S.A., RA Ruderfer D.M., Shakir K., Stenson P.D., Stevens C., Thomas B.P., Tiao G., RA Tusie-Luna M.T., Weisburd B., Won H.H., Yu D., Altshuler D.M., RA Ardissino D., Boehnke M., Danesh J., Donnelly S., Elosua R., Florez J.C., RA Gabriel S.B., Getz G., Glatt S.J., Hultman C.M., Kathiresan S., Laakso M., RA McCarroll S., McCarthy M.I., McGovern D., McPherson R., Neale B.M., RA Palotie A., Purcell S.M., Saleheen D., Scharf J.M., Sklar P., RA Sullivan P.F., Tuomilehto J., Tsuang M.T., Watkins H.C., Wilson J.G., RA Daly M.J., MacArthur D.G.; RT "Analysis of protein-coding genetic variation in 60,706 humans."; RL Nature 536:285-291(2016). CC -!- FUNCTION: Involved in the activation cascade of caspases responsible CC for apoptosis execution. Recruited to both Fas- and TNFR-1 receptors in CC a FADD dependent manner. May participate in the granzyme B apoptotic CC pathways. Cleaves and activates effector caspases CASP3, CASP4, CASP6, CC CASP7, CASP8 and CASP9. Hydrolyzes the small- molecule substrates, Tyr- CC Val-Ala-Asp-|-AMC and Asp-Glu-Val-Asp-|-AMC. CC {ECO:0000269|PubMed:11717445, ECO:0000269|PubMed:16916640}. CC -!- FUNCTION: Isoform 7 can enhance NF-kappaB activity but promotes only CC slight apoptosis. {ECO:0000269|PubMed:17822854}. CC -!- FUNCTION: Isoform C is proteolytically inactive. CC {ECO:0000269|PubMed:11717445}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Strict requirement for Asp at position P1 and has a preferred CC cleavage sequence of Leu-Gln-Thr-Asp-|-Gly.; EC=3.4.22.63; CC Evidence={ECO:0000269|PubMed:16916640}; CC -!- SUBUNIT: Heterotetramer that consists of two anti-parallel arranged CC heterodimers, each one formed by a 23/17 kDa (p23/17) (depending on the CC splicing events) and a 12 kDa (p12) subunit (By similarity). Self- CC associates. Interacts with FADD and CASP8. Found in a Fas signaling CC complex consisting of FAS, FADD, CASP8 and CASP10. Interacts with RFFL CC and RNF34; negatively regulate CASP10 through proteasomal degradation. CC Interacts with RIOK3. {ECO:0000250, ECO:0000269|PubMed:11717445, CC ECO:0000269|PubMed:15069192, ECO:0000269|PubMed:19557502}. CC -!- INTERACTION: CC Q92851; Q14790: CASP8; NbExp=6; IntAct=EBI-495095, EBI-78060; CC Q92851; O15519: CFLAR; NbExp=3; IntAct=EBI-495095, EBI-514941; CC Q92851; Q13158: FADD; NbExp=4; IntAct=EBI-495095, EBI-494804; CC Q92851; O14730: RIOK3; NbExp=6; IntAct=EBI-495095, EBI-1047061; CC Q92851; Q13546: RIPK1; NbExp=2; IntAct=EBI-495095, EBI-358507; CC Q92851; P98170: XIAP; NbExp=3; IntAct=EBI-495095, EBI-517127; CC Q92851-4; PRO_0000004678 [O15519]: CFLAR; NbExp=3; IntAct=EBI-6621134, EBI-4478097; CC Q92851-4; P98170: XIAP; NbExp=3; IntAct=EBI-6621134, EBI-517127; CC Q92851-7; O14730: RIOK3; NbExp=3; IntAct=EBI-12737837, EBI-1047061; CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Name=A; Synonyms=10-A; CC IsoId=Q92851-1; Sequence=Displayed; CC Name=B; Synonyms=10-B, 10-S; CC IsoId=Q92851-2; Sequence=VSP_000819, VSP_000820; CC Name=D; Synonyms=10-D, 10-L; CC IsoId=Q92851-4; Sequence=VSP_000820; CC Name=C; Synonyms=10-C; CC IsoId=Q92851-3; Sequence=VSP_000821, VSP_000822; CC Name=5; CC IsoId=Q92851-5; Sequence=VSP_000819; CC Name=6; CC IsoId=Q92851-6; Sequence=VSP_037229, VSP_000820; CC Name=7; Synonyms=10-G, 10g; CC IsoId=Q92851-7; Sequence=VSP_053333, VSP_053334; CC -!- TISSUE SPECIFICITY: Detectable in most tissues. Lowest expression is CC seen in brain, kidney, prostate, testis and colon. CC -!- PTM: Cleavage by granzyme B and autocatalytic activity generate the two CC active subunits. CC -!- DISEASE: Autoimmune lymphoproliferative syndrome 2A (ALPS2A) CC [MIM:603909]: A disorder of apoptosis that manifests in early childhood CC and results in the accumulation of autoreactive lymphocytes. It is CC characterized by non-malignant lymphadenopathy with hepatosplenomegaly, CC and autoimmune hemolytic anemia, thrombocytopenia and neutropenia. CC {ECO:0000269|PubMed:10412980}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Familial non-Hodgkin lymphoma (NHL) [MIM:605027]: Cancer that CC starts in cells of the lymph system, which is part of the body's immune CC system. NHLs can occur at any age and are often marked by enlarged CC lymph nodes, fever and weight loss. {ECO:0000269|PubMed:12010812}. CC Note=The gene represented in this entry is involved in disease CC pathogenesis. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. {ECO:0000269|PubMed:11973654}. Note=The CC gene represented in this entry is involved in disease pathogenesis. CC -!- MISCELLANEOUS: [Isoform B]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform C]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=CASP10base; Note=CASP10 mutation db; CC URL="https://databases.lovd.nl/shared/genes/CASP10"; CC -!- WEB RESOURCE: Name=Autoimmune Lymphoproliferative Syndrome Database CC (ALPSbase); Note=Caspase-10 mutations causing ALPS type II; CC URL="https://www.niaid.nih.gov/diseases-conditions/autoimmune-lymphoproliferative-syndrome-alps"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U60519; AAC50644.1; -; mRNA. DR EMBL; U86214; AAB46730.1; -; mRNA. DR EMBL; AF111344; AAD28402.1; -; mRNA. DR EMBL; AF111345; AAD28403.1; -; mRNA. DR EMBL; AB038979; BAB32553.1; -; Genomic_DNA. DR EMBL; AB038979; BAB32554.1; -; Genomic_DNA. DR EMBL; AJ487678; CAD32371.1; -; mRNA. DR EMBL; AJ487679; CAD32372.1; -; mRNA. DR EMBL; AY690601; AAU00989.1; -; mRNA. DR EMBL; EF050529; ABJ53426.1; -; Genomic_DNA. DR EMBL; AC007283; AAY24291.1; -; Genomic_DNA. DR EMBL; CH471063; EAW70248.1; -; Genomic_DNA. DR EMBL; CH471063; EAW70249.1; -; Genomic_DNA. DR EMBL; BC042844; AAH42844.1; -; mRNA. DR CCDS; CCDS2338.1; -. [Q92851-1] DR CCDS; CCDS2339.1; -. [Q92851-2] DR CCDS; CCDS2340.1; -. [Q92851-4] DR CCDS; CCDS56159.1; -. [Q92851-6] DR CCDS; CCDS56160.1; -. [Q92851-5] DR CCDS; CCDS77506.1; -. [Q92851-7] DR RefSeq; NP_001193453.1; NM_001206524.2. [Q92851-6] DR RefSeq; NP_001193471.1; NM_001206542.2. [Q92851-5] DR RefSeq; NP_001221.2; NM_001230.4. [Q92851-2] DR RefSeq; NP_001293012.1; NM_001306083.2. [Q92851-7] DR RefSeq; NP_116756.2; NM_032974.4. [Q92851-1] DR RefSeq; NP_116758.1; NM_032976.4. [Q92851-3] DR RefSeq; NP_116759.2; NM_032977.3. [Q92851-4] DR AlphaFoldDB; Q92851; -. DR SMR; Q92851; -. DR BioGRID; 107293; 98. DR CORUM; Q92851; -. DR FunCoup; Q92851; 364. DR IntAct; Q92851; 26. DR MINT; Q92851; -. DR STRING; 9606.ENSP00000286186; -. DR BindingDB; Q92851; -. DR ChEMBL; CHEMBL5037; -. DR MEROPS; C14.011; -. DR iPTMnet; Q92851; -. DR PhosphoSitePlus; Q92851; -. DR BioMuta; CASP10; -. DR DMDM; 12644463; -. DR CPTAC; CPTAC-1039; -. DR jPOST; Q92851; -. DR MassIVE; Q92851; -. DR PaxDb; 9606-ENSP00000286186; -. DR PeptideAtlas; Q92851; -. DR ProteomicsDB; 66146; -. DR ProteomicsDB; 75543; -. [Q92851-1] DR ProteomicsDB; 75544; -. [Q92851-2] DR ProteomicsDB; 75545; -. [Q92851-3] DR ProteomicsDB; 75546; -. [Q92851-4] DR ProteomicsDB; 75547; -. [Q92851-5] DR ProteomicsDB; 75548; -. [Q92851-6] DR Pumba; Q92851; -. DR Antibodypedia; 1700; 590 antibodies from 47 providers. DR DNASU; 843; -. DR Ensembl; ENST00000272879.9; ENSP00000272879.5; ENSG00000003400.17. [Q92851-1] DR Ensembl; ENST00000286186.11; ENSP00000286186.6; ENSG00000003400.17. [Q92851-4] DR Ensembl; ENST00000313728.12; ENSP00000314599.7; ENSG00000003400.17. [Q92851-6] DR Ensembl; ENST00000346817.10; ENSP00000237865.7; ENSG00000003400.17. [Q92851-2] DR Ensembl; ENST00000374650.8; ENSP00000363781.3; ENSG00000003400.17. [Q92851-7] DR Ensembl; ENST00000448480.1; ENSP00000396835.1; ENSG00000003400.17. [Q92851-5] DR Ensembl; ENST00000492363.6; ENSP00000512459.1; ENSG00000003400.17. [Q92851-3] DR GeneID; 843; -. DR KEGG; hsa:843; -. DR MANE-Select; ENST00000286186.11; ENSP00000286186.6; NM_032977.4; NP_116759.2. [Q92851-4] DR UCSC; uc002uxi.2; human. [Q92851-1] DR AGR; HGNC:1500; -. DR ClinPGx; PA26084; -. DR CTD; 843; -. DR DisGeNET; 843; -. DR GeneCards; CASP10; -. DR GeneReviews; CASP10; -. DR HGNC; HGNC:1500; CASP10. DR HPA; ENSG00000003400; Low tissue specificity. DR MalaCards; CASP10; -. DR MIM; 601762; gene. DR MIM; 603909; phenotype. DR MIM; 605027; phenotype. DR MIM; 613659; phenotype. DR OpenTargets; ENSG00000003400; -. DR Orphanet; 3261; Autoimmune lymphoproliferative syndrome. DR VEuPathDB; HostDB:ENSG00000003400; -. DR eggNOG; KOG3573; Eukaryota. DR GeneTree; ENSGT00940000160994; -. DR HOGENOM; CLU_088972_0_0_1; -. DR InParanoid; Q92851; -. DR OMA; CRDCISH; -. DR OrthoDB; 6114029at2759; -. DR PAN-GO; Q92851; 6 GO annotations based on evolutionary models. DR PhylomeDB; Q92851; -. DR BioCyc; MetaCyc:HS00093-MONOMER; -. DR BRENDA; 3.4.22.63; 2681. DR PathwayCommons; Q92851; -. DR Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases. DR Reactome; R-HSA-75157; FasL/ CD95L signaling. DR Reactome; R-HSA-75158; TRAIL signaling. DR Reactome; R-HSA-933543; NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10. DR SignaLink; Q92851; -. DR SIGNOR; Q92851; -. DR Agora; ENSG00000003400; -. DR BioGRID-ORCS; 843; 6 hits in 1156 CRISPR screens. DR ChiTaRS; CASP10; human. DR GeneWiki; Caspase_10; -. DR GenomeRNAi; 843; -. DR Pharos; Q92851; Tchem. DR PRO; PR:Q92851; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q92851; protein. DR Bgee; ENSG00000003400; Expressed in colonic epithelium and 126 other cell types or tissues. DR ExpressionAtlas; Q92851; baseline and differential. DR GO; GO:0031265; C:CD95 death-inducing signaling complex; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0097342; C:ripoptosome; IDA:UniProtKB. DR GO; GO:0004197; F:cysteine-type endopeptidase activity; IDA:UniProtKB. DR GO; GO:0035877; F:death effector domain binding; IPI:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:0006915; P:apoptotic process; IBA:GO_Central. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IMP:UniProtKB. DR GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IDA:UniProt. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IBA:GO_Central. DR GO; GO:0051604; P:protein maturation; IDA:UniProt. DR GO; GO:0006508; P:proteolysis; IEA:UniProtKB-KW. DR CDD; cd00032; CASc; 1. DR CDD; cd08341; DED_Caspase_10_r1; 1. DR CDD; cd08814; DED_Caspase_10_r2; 1. DR FunFam; 1.10.533.10:FF:000038; Caspase 10; 1. DR FunFam; 1.10.533.10:FF:000070; Caspase 10; 1. DR FunFam; 3.40.50.1460:FF:000014; Caspase 10, apoptosis-related cysteine peptidase; 1. DR Gene3D; 3.40.50.1460; -; 1. DR Gene3D; 1.10.533.10; Death Domain, Fas; 2. DR InterPro; IPR035701; CASP10_DED2. DR InterPro; IPR029030; Caspase-like_dom_sf. DR InterPro; IPR033139; Caspase_cys_AS. DR InterPro; IPR016129; Caspase_his_AS. DR InterPro; IPR011029; DEATH-like_dom_sf. DR InterPro; IPR001875; DED_dom. DR InterPro; IPR011600; Pept_C14_caspase. DR InterPro; IPR002138; Pept_C14_p10. DR InterPro; IPR001309; Pept_C14_p20. DR InterPro; IPR015917; Pept_C14A. DR PANTHER; PTHR48169:SF7; CASPASE 10; 1. DR PANTHER; PTHR48169; DED DOMAIN-CONTAINING PROTEIN; 1. DR Pfam; PF01335; DED; 2. DR Pfam; PF00656; Peptidase_C14; 1. DR PRINTS; PR00376; IL1BCENZYME. DR SMART; SM00115; CASc; 1. DR SMART; SM00031; DED; 2. DR SUPFAM; SSF52129; Caspase-like; 1. DR SUPFAM; SSF47986; DEATH domain; 2. DR PROSITE; PS01122; CASPASE_CYS; 1. DR PROSITE; PS01121; CASPASE_HIS; 1. DR PROSITE; PS50207; CASPASE_P10; 1. DR PROSITE; PS50208; CASPASE_P20; 1. DR PROSITE; PS50168; DED; 2. PE 1: Evidence at protein level; KW Alternative splicing; Apoptosis; Direct protein sequencing; KW Disease variant; Hydrolase; Protease; Proteomics identification; KW Reference proteome; Repeat; Thiol protease; Zymogen. FT PROPEP 1..219 FT /id="PRO_0000004644" FT CHAIN 220..415 FT /note="Caspase-10 subunit p23/17" FT /id="PRO_0000004645" FT CHAIN 416..521 FT /note="Caspase-10 subunit p12" FT /id="PRO_0000004646" FT DOMAIN 19..97 FT /note="DED 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00065" FT DOMAIN 114..187 FT /note="DED 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00065" FT REGION 231..269 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 231..248 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 259..268 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 358 FT /evidence="ECO:0000250" FT ACT_SITE 401 FT /evidence="ECO:0000250" FT VAR_SEQ 229..271 FT /note="Missing (in isoform B and isoform 5)" FT /evidence="ECO:0000303|PubMed:8755496, ECO:0000303|Ref.5" FT /id="VSP_000819" FT VAR_SEQ 229..247 FT /note="QESWQNKHAGSNGNRATNG -> EGVFVFLNEGDRGNSPDDL (in FT isoform 7)" FT /evidence="ECO:0000303|PubMed:17822854" FT /id="VSP_053333" FT VAR_SEQ 241..307 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000303|Ref.5" FT /id="VSP_037229" FT VAR_SEQ 241..273 FT /note="GNRATNGAPSLVSRGMQGASANTLNSETSTKRA -> EGSCVQDESEPQRPL FT CHCQQPQLYLPEGQTRNP (in isoform C)" FT /evidence="ECO:0000303|PubMed:10187817" FT /id="VSP_000821" FT VAR_SEQ 248..521 FT /note="Missing (in isoform 7)" FT /evidence="ECO:0000303|PubMed:17822854" FT /id="VSP_053334" FT VAR_SEQ 274..521 FT /note="Missing (in isoform C)" FT /evidence="ECO:0000303|PubMed:10187817" FT /id="VSP_000822" FT VAR_SEQ 473..521 FT /note="MLKFLEKTMEIRGRKRTVWGAKQISATSLPTAISAQTPRPPMRRWSSVS -> FT HEDILSILTAVNDDVSRRVDKQGTKKQMPQPAFTLRKKLVFPVPLDALSL (in FT isoform B, isoform D and isoform 6)" FT /evidence="ECO:0000303|PubMed:10187817, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8755496, FT ECO:0000303|Ref.5" FT /id="VSP_000820" FT VARIANT 14 FT /note="K -> T (found in a colon cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:20025484" FT /id="VAR_065233" FT VARIANT 21 FT /note="R -> C (found in a multiple myeloma sample; somatic FT mutation; dbSNP:rs559979934)" FT /evidence="ECO:0000269|PubMed:19900088" FT /id="VAR_065234" FT VARIANT 147 FT /note="M -> T (in GASC; somatic mutation; impairs CASP10- FT mediated apoptosis; dbSNP:rs121909776)" FT /evidence="ECO:0000269|PubMed:11973654" FT /id="VAR_037428" FT VARIANT 239 FT /note="S -> C (in dbSNP:rs41473647)" FT /id="VAR_055361" FT VARIANT 285 FT /note="L -> F (in ALPS2A; dbSNP:rs17860403)" FT /evidence="ECO:0000269|PubMed:10412980" FT /id="VAR_014071" FT VARIANT 285 FT /note="L -> P (found in a T-acute lymphoblastic leukemia FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:19900088" FT /id="VAR_065235" FT VARIANT 406 FT /note="I -> L (the mutant protein has defective apoptosis FT and exerts a dominant-negative effect when cotransfected FT with the wild-type protein; dbSNP:rs80358239)" FT /evidence="ECO:0000269|PubMed:16446975, FT ECO:0000269|PubMed:27378136, ECO:0000269|PubMed:27535533" FT /id="VAR_037429" FT VARIANT 410 FT /note="V -> I (does not interfere with apoptosis in a FT dominant negative manner; dbSNP:rs13010627)" FT /evidence="ECO:0000269|PubMed:10187817, FT ECO:0000269|PubMed:10412980, ECO:0000269|PubMed:16446975" FT /id="VAR_014072" FT VARIANT 414 FT /note="A -> V (in NHL; somatic mutation; dbSNP:rs28936699)" FT /evidence="ECO:0000269|PubMed:12010812" FT /id="VAR_037430" FT VARIANT 444 FT /note="P -> S (in dbSNP:rs41513147)" FT /id="VAR_055362" FT VARIANT 446 FT /note="Y -> C (risk factor for ALPS2A; does not interfere FT with apoptosis in a dominant negative manner; FT dbSNP:rs17860405)" FT /evidence="ECO:0000269|PubMed:16446975" FT /id="VAR_037431" FT MUTAGEN 401 FT /note="C->A: Abolishes proteolytic activity." FT /evidence="ECO:0000269|PubMed:11717445" FT CONFLICT 68 FT /note="E -> G (in Ref. 2; AAB46730)" FT /evidence="ECO:0000305" FT CONFLICT 268 FT /note="T -> A (in Ref. 3; AAD28403)" FT /evidence="ECO:0000305" FT VARIANT Q92851-2:479 FT /note="L -> I (in dbSNP:rs13006529)" FT /evidence="ECO:0000269|PubMed:11161814, FT ECO:0000269|PubMed:8755496" FT /id="VAR_082802" FT VARIANT Q92851-4:522 FT /note="L -> I (in dbSNP:rs13006529)" FT /evidence="ECO:0000305" FT /id="VAR_082803" FT VARIANT Q92851-6:455 FT /note="L -> I (in dbSNP:rs13006529)" FT /evidence="ECO:0000305" FT /id="VAR_082804" SQ SEQUENCE 521 AA; 58951 MW; 840348AE602B8243 CRC64; MKSQGQHWYS SSDKNCKVSF REKLLIIDSN LGVQDVENLK FLCIGLVPNK KLEKSSSASD VFEHLLAEDL LSEEDPFFLA ELLYIIRQKK LLQHLNCTKE EVERLLPTRQ RVSLFRNLLY ELSEGIDSEN LKDMIFLLKD SLPKTEMTSL SFLAFLEKQG KIDEDNLTCL EDLCKTVVPK LLRNIEKYKR EKAIQIVTPP VDKEAESYQG EEELVSQTDV KTFLEALPQE SWQNKHAGSN GNRATNGAPS LVSRGMQGAS ANTLNSETST KRAAVYRMNR NHRGLCVIVN NHSFTSLKDR QGTHKDAEIL SHVFQWLGFT VHIHNNVTKV EMEMVLQKQK CNPAHADGDC FVFCILTHGR FGAVYSSDEA LIPIREIMSH FTALQCPRLA EKPKLFFIQA CQGEEIQPSV SIEADALNPE QAPTSLQDSI PAEADFLLGL ATVPGYVSFR HVEEGSWYIQ SLCNHLKKLV PRMLKFLEKT MEIRGRKRTV WGAKQISATS LPTAISAQTP RPPMRRWSSV S // ID CEMIP_HUMAN Reviewed; 1361 AA. AC Q8WUJ3; Q6L9J5; Q9H1K5; Q9NPN9; Q9ULM1; DT 13-APR-2004, integrated into UniProtKB/Swiss-Prot. DT 13-APR-2004, sequence version 2. DT 28-JAN-2026, entry version 168. DE RecName: Full=Cell migration-inducing and hyaluronan-binding protein; DE EC=3.2.1.35 {ECO:0000269|PubMed:23509262, ECO:0000269|PubMed:24269685}; DE AltName: Full=Hyaluronan binding protein involved in hyaluronan depolymerization {ECO:0000303|PubMed:23509262}; DE Flags: Precursor; GN Name=CEMIP {ECO:0000312|HGNC:HGNC:29213}; GN Synonyms=HYBID {ECO:0000303|PubMed:23509262}, KIAA1199; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], VARIANTS CYS-187; HIS-187 AND TYR-783, AND RP VARIANTS ARG-783; ILE-1109 AND ALA-1169. RX PubMed=14577002; DOI=10.1007/s10038-003-0079-2; RA Abe S., Usami S., Nakamura Y.; RT "Mutations in the gene encoding KIAA1199 protein, an inner-ear protein RT expressed in Deiters' cells and the fibrocytes, as the cause of RT nonsyndromic hearing loss."; RL J. Hum. Genet. 48:564-570(2003). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=16157444; DOI=10.1016/j.canlet.2005.07.028; RA Michishita E., Garces G., Barrett J.C., Horikawa I.; RT "Upregulation of the KIAA1199 gene is associated with cellular mortality."; RL Cancer Lett. 239:71-77(2006). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 349-1361 (ISOFORM 1), AND TISSUE RP SPECIFICITY. RC TISSUE=Brain; RX PubMed=10574462; DOI=10.1093/dnares/6.5.337; RA Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XV. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 6:337-345(1999). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 558-1361. RG The European IMAGE consortium; RL Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 862-1361. RX PubMed=11247670; DOI=10.1006/geno.2000.6466; RA Wines M.E., Lee L., Katari M.S., Zhang L., DeRossi C., Shi Y., Perkins S., RA Feldman M., McCombie W.R., Holdener B.C.; RT "Identification of mesoderm development (mesd) candidate genes by RT comparative mapping and genome sequence analysis."; RL Genomics 72:88-98(2001). RN [8] RP TISSUE SPECIFICITY. RX PubMed=12471561; DOI=10.1086/345398; RA Abe S., Katagiri T., Saito-Hisaminato A., Usami S., Inoue Y., Tsunoda T., RA Nakamura Y.; RT "Identification of CRYM as a candidate responsible for nonsyndromic RT deafness, through cDNA microarray analysis of human cochlear and vestibular RT tissues."; RL Am. J. Hum. Genet. 72:73-82(2003). RN [9] RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=19434458; DOI=10.1245/s10434-009-0469-6; RA Matsuzaki S., Tanaka F., Mimori K., Tahara K., Inoue H., Mori M.; RT "Clinicopathologic significance of KIAA1199 overexpression in human gastric RT cancer."; RL Ann. Surg. Oncol. 16:2042-2051(2009). RN [10] RP PROBABLE FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RX PubMed=21772334; DOI=10.1038/bjc.2011.268; RA Birkenkamp-Demtroder K., Maghnouj A., Mansilla F., Thorsen K., RA Andersen C.L., Oster B., Hahn S., Orntoft T.F.; RT "Repression of KIAA1199 attenuates Wnt-signalling and decreases the RT proliferation of colon cancer cells."; RL Br. J. Cancer 105:552-561(2011). RN [11] RP TISSUE SPECIFICITY, AND INDUCTION. RX PubMed=22970280; DOI=10.1371/journal.pone.0044661; RA Kuscu C., Evensen N., Kim D., Hu Y.J., Zucker S., Cao J.; RT "Transcriptional and epigenetic regulation of KIAA1199 gene expression in RT human breast cancer."; RL PLoS ONE 7:E44661-E44661(2012). RN [12] RP FUNCTION IN CANCER, INTERACTION WITH HSPA5, SUBCELLULAR LOCATION, AND RP TISSUE SPECIFICITY. RX PubMed=23990668; DOI=10.1093/jnci/djt224; RA Evensen N.A., Kuscu C., Nguyen H.L., Zarrabi K., Dufour A., Kadam P., RA Hu Y.J., Pulkoski-Gross A., Bahou W.F., Zucker S., Cao J.; RT "Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in RT cancer cell migration."; RL J. Natl. Cancer Inst. 105:1402-1416(2013). RN [13] RP INTERACTION WITH EPHA2 AND ITPR3, GLYCOSYLATION, SUBCELLULAR LOCATION, AND RP TISSUE SPECIFICITY. RX PubMed=23936024; DOI=10.1371/journal.pone.0069473; RA Tiwari A., Schneider M., Fiorino A., Haider R., Okoniewski M.J., RA Roschitzki B., Uzozie A., Menigatti M., Jiricny J., Marra G.; RT "Early insights into the function of KIAA1199, a markedly overexpressed RT protein in human colorectal tumors."; RL PLoS ONE 8:E69473-E69473(2013). RN [14] RP FUNCTION IN HYALURONIC ACID DEGRADATION, CATALYTIC ACTIVITY, ACTIVITY RP REGULATION, HYALURONIC ACID-BINDING, INTERACTION WITH CLATHRIN, SUBCELLULAR RP LOCATION, INDUCTION, AND CHARACTERIZATION OF VARIANTS CYS-187; HIS-187; RP ARG-783 AND ILE-1109. RX PubMed=23509262; DOI=10.1073/pnas.1215432110; RA Yoshida H., Nagaoka A., Kusaka-Kikushima A., Tobiishi M., Kawabata K., RA Sayo T., Sakai S., Sugiyama Y., Enomoto H., Okada Y., Inoue S.; RT "KIAA1199, a deafness gene of unknown function, is a new hyaluronan binding RT protein involved in hyaluronan depolymerization."; RL Proc. Natl. Acad. Sci. U.S.A. 110:5612-5617(2013). RN [15] RP FUNCTION IN HYALURONIC ACID DEGRADATION, CATALYTIC ACTIVITY, GLYCOSYLATION, RP SUBCELLULAR LOCATION, PROTEOLYTIC PROCESSING, AND SIGNAL SEQUENCE CLEAVAGE RP SITE. RX PubMed=24269685; DOI=10.1016/j.febslet.2013.11.017; RA Yoshida H., Nagaoka A., Nakamura S., Tobiishi M., Sugiyama Y., Inoue S.; RT "N-Terminal signal sequence is required for cellular trafficking and RT hyaluronan-depolymerization of KIAA1199."; RL FEBS Lett. 588:111-116(2014). CC -!- FUNCTION: Mediates depolymerization of hyaluronic acid (HA) via the CC cell membrane-associated clathrin-coated pit endocytic pathway. Binds CC to hyaluronic acid. Hydrolyzes high molecular weight hyaluronic acid to CC produce an intermediate-sized product, a process that may occur through CC rapid vesicle endocytosis and recycling without intracytoplasmic CC accumulation or digestion in lysosomes. Involved in hyaluronan CC catabolism in the dermis of the skin and arthritic synovium. Positively CC regulates epithelial-mesenchymal transition (EMT), and hence tumor cell CC growth, invasion and cancer dissemination. In collaboration with CC HSPA5/BIP, promotes cancer cell migration in a calcium and PKC- CC dependent manner. May be involved in hearing. CC {ECO:0000269|PubMed:23509262, ECO:0000269|PubMed:23990668, CC ECO:0000269|PubMed:24269685}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D- CC glucosamine and D-glucuronate residues in hyaluronate.; EC=3.2.1.35; CC Evidence={ECO:0000269|PubMed:23509262, ECO:0000269|PubMed:24269685}; CC -!- ACTIVITY REGULATION: Activity is up-regulated by histamine. CC {ECO:0000269|PubMed:23509262}. CC -!- SUBUNIT: Interacts with EPHA2 and ITPR3. Interacts with HSPA5/BIP; the CC interaction induces calcium leakage from the endoplasmic reticulum and CC cell migration. Interacts with clathrin heavy chain/CLTC. CC {ECO:0000269|PubMed:23509262, ECO:0000269|PubMed:23936024, CC ECO:0000269|PubMed:23990668}. CC -!- INTERACTION: CC Q8WUJ3; P53621: COPA; NbExp=2; IntAct=EBI-310606, EBI-356273; CC Q8WUJ3; Q93100: PHKB; NbExp=2; IntAct=EBI-310606, EBI-740559; CC -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Endoplasmic reticulum. Cell CC membrane. Membrane, clathrin-coated pit. Secreted. Note=Retained in the CC endoplasmic reticulum (ER) in a HSPA5/BIP-dependent manner. Colocalized CC with clathrin heavy chain/CLTC in clathrin-coated vesicles. Strongly CC detected in the cytoplasm of breast carcinoma cells, whereas poorly CC detected in adjacent normal epithelial cells, stromal cells, or benign CC breast tissues. Localized in the nucleus and cytoplasm of colon CC adenocarcinomas. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q8WUJ3-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8WUJ3-2; Sequence=VSP_009814, VSP_009815; CC -!- TISSUE SPECIFICITY: Expressed in dermal and in synovial fibroblasts. CC Strongly expressed in gastric cancers compared with the paired normal CC tissues. Strongly expressed in both ductal carcinoma and invasive CC breast cancer cells compared with benign epithelial cells (at protein CC level). Strongly expressed in brain, placenta, prostate, breast, lung CC and testis. Expressed in fibroblasts, epithelial cells and cancer CC cells. In ear, it is specifically expressed in inner ear. Expressed in CC cochlea and vestibule tissues. Strongly expressed in gastric cancers CC compared with the paired normal tissues. Strongly expressed in colon CC adenocarcinomas compared with normal colonic mucosas. Strongly CC expressed in breast cancer as compared to normal breast tissue. CC {ECO:0000269|PubMed:10574462, ECO:0000269|PubMed:12471561, CC ECO:0000269|PubMed:16157444, ECO:0000269|PubMed:19434458, CC ECO:0000269|PubMed:21772334, ECO:0000269|PubMed:22970280, CC ECO:0000269|PubMed:23936024, ECO:0000269|PubMed:23990668}. CC -!- INDUCTION: Up-regulated by histamine. Up-regulated by the adapter CC protein complex 1 (AP-1) and NF-kappaB/RELA. Down-regulated by CC transforming growth factor TGFB1. {ECO:0000269|PubMed:22970280, CC ECO:0000269|PubMed:23509262}. CC -!- DOMAIN: The signal sequence is essential in mediating its proper CC translocation, hyaluronic acid (HA) degradation activity and secretion. CC -!- PTM: N-glycosylated; glycosylation is not necessary for HA-binding. CC {ECO:0000269|PubMed:23936024, ECO:0000269|PubMed:24269685}. CC -!- SIMILARITY: Belongs to the CEMIP family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB103330; BAD02451.1; -; mRNA. DR EMBL; CH471136; EAW99111.1; -; Genomic_DNA. DR EMBL; BC020256; AAH20256.1; -; mRNA. DR EMBL; AB033025; BAA86513.1; -; mRNA. DR EMBL; AL359061; CAB94391.1; -; mRNA. DR EMBL; AY007811; AAG41059.1; -; mRNA. DR CCDS; CCDS10315.1; -. [Q8WUJ3-1] DR RefSeq; NP_001280227.1; NM_001293298.2. [Q8WUJ3-1] DR RefSeq; NP_001280233.1; NM_001293304.2. [Q8WUJ3-1] DR RefSeq; NP_061159.1; NM_018689.3. [Q8WUJ3-1] DR RefSeq; XP_047288856.1; XM_047432900.1. [Q8WUJ3-1] DR RefSeq; XP_054234488.1; XM_054378513.1. [Q8WUJ3-1] DR AlphaFoldDB; Q8WUJ3; -. DR SMR; Q8WUJ3; -. DR BioGRID; 121452; 96. DR FunCoup; Q8WUJ3; 405. DR IntAct; Q8WUJ3; 15. DR MINT; Q8WUJ3; -. DR STRING; 9606.ENSP00000378177; -. DR CarbonylDB; Q8WUJ3; -. DR GlyCosmos; Q8WUJ3; 7 sites, No reported glycans. DR GlyGen; Q8WUJ3; 8 sites, 3 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; Q8WUJ3; -. DR PhosphoSitePlus; Q8WUJ3; -. DR BioMuta; CEMIP; -. DR DMDM; 46396475; -. DR jPOST; Q8WUJ3; -. DR MassIVE; Q8WUJ3; -. DR PaxDb; 9606-ENSP00000378177; -. DR PeptideAtlas; Q8WUJ3; -. DR ProteomicsDB; 74690; -. [Q8WUJ3-1] DR ProteomicsDB; 74691; -. [Q8WUJ3-2] DR Antibodypedia; 27890; 248 antibodies from 26 providers. DR DNASU; 57214; -. DR Ensembl; ENST00000220244.7; ENSP00000220244.3; ENSG00000103888.18. [Q8WUJ3-1] DR Ensembl; ENST00000356249.9; ENSP00000348583.5; ENSG00000103888.18. [Q8WUJ3-1] DR Ensembl; ENST00000394685.8; ENSP00000378177.3; ENSG00000103888.18. [Q8WUJ3-1] DR GeneID; 57214; -. DR KEGG; hsa:57214; -. DR MANE-Select; ENST00000394685.8; ENSP00000378177.3; NM_001293298.2; NP_001280227.1. DR UCSC; uc002bfw.2; human. [Q8WUJ3-1] DR AGR; HGNC:29213; -. DR ClinPGx; PA134967531; -. DR CTD; 57214; -. DR DisGeNET; 57214; -. DR GeneCards; CEMIP; -. DR HGNC; HGNC:29213; CEMIP. DR HPA; ENSG00000103888; Tissue enhanced (endometrium). DR MIM; 608366; gene. DR OpenTargets; ENSG00000103888; -. DR VEuPathDB; HostDB:ENSG00000103888; -. DR eggNOG; ENOG502QT0K; Eukaryota. DR GeneTree; ENSGT00940000153636; -. DR HOGENOM; CLU_005606_1_0_1; -. DR InParanoid; Q8WUJ3; -. DR OMA; YGRADED; -. DR OrthoDB; 120976at2759; -. DR PAN-GO; Q8WUJ3; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q8WUJ3; -. DR PathwayCommons; Q8WUJ3; -. DR Reactome; R-HSA-2160916; Hyaluronan degradation. DR SignaLink; Q8WUJ3; -. DR Agora; ENSG00000103888; -. DR BioGRID-ORCS; 57214; 16 hits in 1143 CRISPR screens. DR ChiTaRS; CEMIP; human. DR GeneWiki; KIAA1199; -. DR GenomeRNAi; 57214; -. DR Pharos; Q8WUJ3; Tbio. DR PRO; PR:Q8WUJ3; -. DR Proteomes; UP000005640; Chromosome 15. DR RNAct; Q8WUJ3; protein. DR Bgee; ENSG00000103888; Expressed in choroid plexus epithelium and 132 other cell types or tissues. DR ExpressionAtlas; Q8WUJ3; baseline and differential. DR GO; GO:0045334; C:clathrin-coated endocytic vesicle; IDA:UniProtKB. DR GO; GO:0005905; C:clathrin-coated pit; IEA:UniProtKB-SubCell. DR GO; GO:0030665; C:clathrin-coated vesicle membrane; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0001650; C:fibrillar center; IDA:HPA. DR GO; GO:0031965; C:nuclear membrane; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW. DR GO; GO:0032050; F:clathrin heavy chain binding; IDA:UniProtKB. DR GO; GO:0046923; F:ER retention sequence binding; IDA:UniProtKB. DR GO; GO:0005540; F:hyaluronic acid binding; IDA:UniProtKB. DR GO; GO:0004415; F:hyalurononglucosaminidase activity; IMP:UniProtKB. DR GO; GO:0030214; P:hyaluronan catabolic process; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB. DR GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:1900020; P:positive regulation of protein kinase C activity; IDA:UniProtKB. DR GO; GO:0090314; P:positive regulation of protein targeting to membrane; IDA:UniProtKB. DR GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IDA:UniProtKB. DR GO; GO:0007605; P:sensory perception of sound; IMP:UniProtKB. DR CDD; cd13941; PANDER_like_KIAA1199; 1. DR CDD; cd13938; PANDER_like_TMEM2; 1. DR InterPro; IPR052252; CEMIP/CEMIP2. DR InterPro; IPR055401; CEMIP_beta-hel_dom. DR InterPro; IPR055400; CEMIP_X. DR InterPro; IPR019316; G8_domain. DR InterPro; IPR039477; ILEI/PANDER_dom. DR InterPro; IPR011050; Pectin_lyase_fold/virulence. DR InterPro; IPR039473; TMEM2_PANDER-like. DR InterPro; IPR025155; WxxW_domain. DR PANTHER; PTHR15535:SF15; CELL MIGRATION-INDUCING AND HYALURONAN-BINDING PROTEIN; 1. DR PANTHER; PTHR15535; TRANSMEMBRANE PROTEIN 2-RELATED; 1. DR Pfam; PF24606; CEMIP_beta-hel; 1. DR Pfam; PF24605; CEMIP_X; 1. DR Pfam; PF10162; G8; 1. DR Pfam; PF15711; ILEI; 2. DR Pfam; PF13330; Mucin2_WxxW; 2. DR SMART; SM01225; G8; 1. DR SUPFAM; SSF51126; Pectin lyase-like; 1. DR PROSITE; PS51484; G8; 1. DR PROSITE; PS52031; GG_LECTIN; 2. PE 1: Evidence at protein level; KW Alternative splicing; Cell membrane; Coated pit; Cytoplasm; KW Endoplasmic reticulum; Glycoprotein; Glycosidase; Hyaluronic acid; KW Hydrolase; Lectin; Membrane; Nucleus; Proteomics identification; KW Reference proteome; Repeat; Secreted; Signal. FT SIGNAL 1..30 FT /evidence="ECO:0000269|PubMed:24269685" FT CHAIN 31..1361 FT /note="Cell migration-inducing and hyaluronan-binding FT protein" FT /id="PRO_0000021538" FT DOMAIN 44..166 FT /note="G8" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00817" FT DOMAIN 176..317 FT /note="GG-type lectin 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01375" FT REPEAT 572..594 FT /note="PbH1 1" FT REPEAT 595..617 FT /note="PbH1 2" FT REPEAT 719..741 FT /note="PbH1 3" FT REPEAT 798..819 FT /note="PbH1 4" FT DOMAIN 1227..1361 FT /note="GG-type lectin 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01375" FT REGION 295..591 FT /note="Necessary for its endoplasmic reticulum (ER) FT retention and interaction with HSPA5" FT /evidence="ECO:0000269|PubMed:23990668" FT CARBOHYD 119 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 165 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 312 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 370 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 420 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 889 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 921 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 978..992 FT /note="NWLVRHPDCINVPDW -> KWHSLASKAASGPSG (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_009814" FT VAR_SEQ 993..1361 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_009815" FT VARIANT 187 FT /note="R -> C (in a family with non-syndromic hearing loss; FT reduces hyaluronic acid degradation activity; FT dbSNP:rs368854657)" FT /evidence="ECO:0000269|PubMed:14577002, FT ECO:0000269|PubMed:23509262" FT /id="VAR_018165" FT VARIANT 187 FT /note="R -> H (in two unrelated families with non-syndromic FT hearing loss; reduces hyaluronic acid (HA) degradation FT activity; dbSNP:rs144446375)" FT /evidence="ECO:0000269|PubMed:14577002, FT ECO:0000269|PubMed:23509262" FT /id="VAR_018166" FT VARIANT 783 FT /note="H -> R (does not inhibit hyaluronic acid degradation FT activity; dbSNP:rs12441101)" FT /evidence="ECO:0000269|PubMed:14577002, FT ECO:0000269|PubMed:23509262" FT /id="VAR_018167" FT VARIANT 783 FT /note="H -> Y (in a sporadic case of non-syndromic hearing FT loss; dbSNP:rs996035812)" FT /evidence="ECO:0000269|PubMed:14577002" FT /id="VAR_018168" FT VARIANT 1109 FT /note="V -> I (does not inhibit hyaluronic acid degradation FT activity; dbSNP:rs751807711)" FT /evidence="ECO:0000269|PubMed:14577002, FT ECO:0000269|PubMed:23509262" FT /id="VAR_018169" FT VARIANT 1169 FT /note="P -> A (in dbSNP:rs16972583)" FT /evidence="ECO:0000269|PubMed:14577002" FT /id="VAR_018170" FT CONFLICT 558..564 FT /note="HFHLAGD -> TRPPTRP (in Ref. 6; CAB94391)" FT /evidence="ECO:0000305" FT CONFLICT 862 FT /note="H -> T (in Ref. 7; AAG41059)" FT /evidence="ECO:0000305" SQ SEQUENCE 1361 AA; 152998 MW; 40CDFFB84F99516C CRC64; MGAAGRQDFL FKAMLTISWL TLTCFPGATS TVAAGCPDQS PELQPWNPGH DQDHHVHIGQ GKTLLLTSSA TVYSIHISEG GKLVIKDHDE PIVLRTRHIL IDNGGELHAG SALCPFQGNF TIILYGRADE GIQPDPYYGL KYIGVGKGGA LELHGQKKLS WTFLNKTLHP GGMAEGGYFF ERSWGHRGVI VHVIDPKSGT VIHSDRFDTY RSKKESERLV QYLNAVPDGR ILSVAVNDEG SRNLDDMARK AMTKLGSKHF LHLGFRHPWS FLTVKGNPSS SVEDHIEYHG HRGSAAARVF KLFQTEHGEY FNVSLSSEWV QDVEWTEWFD HDKVSQTKGG EKISDLWKAH PGKICNRPID IQATTMDGVN LSTEVVYKKG QDYRFACYDR GRACRSYRVR FLCGKPVRPK LTVTIDTNVN STILNLEDNV QSWKPGDTLV IASTDYSMYQ AEEFQVLPCR SCAPNQVKVA GKPMYLHIGE EIDGVDMRAE VGLLSRNIIV MGEMEDKCYP YRNHICNFFD FDTFGGHIKF ALGFKAAHLE GTELKHMGQQ LVGQYPIHFH LAGDVDERGG YDPPTYIRDL SIHHTFSRCV TVHGSNGLLI KDVVGYNSLG HCFFTEDGPE ERNTFDHCLG LLVKSGTLLP SDRDSKMCKM ITEDSYPGYI PKPRQDCNAV STFWMANPNN NLINCAAAGS EETGFWFIFH HVPTGPSVGM YSPGYSEHIP LGKFYNNRAH SNYRAGMIID NGVKTTEASA KDKRPFLSII SARYSPHQDA DPLKPREPAI IRHFIAYKNQ DHGAWLRGGD VWLDSCRFAD NGIGLTLASG GTFPYDDGSK QEIKNSLFVG ESGNVGTEMM DNRIWGPGGL DHSGRTLPIG QNFPIRGIQL YDGPINIQNC TFRKFVALEG RHTSALAFRL NNAWQSCPHN NVTGIAFEDV PITSRVFFGE PGPWFNQLDM DGDKTSVFHD VDGSVSEYPG SYLTKNDNWL VRHPDCINVP DWRGAICSGC YAQMYIQAYK TSNLRMKIIK NDFPSHPLYL EGALTRSTHY QQYQPVVTLQ KGYTIHWDQT APAELAIWLI NFNKGDWIRV GLCYPRGTTF SILSDVHNRL LKQTSKTGVF VRTLQMDKVE QSYPGRSHYY WDEDSGLLFL KLKAQNEREK FAFCSMKGCE RIKIKALIPK NAGVSDCTAT AYPKFTERAV VDVPMPKKLF GSQLKTKDHF LEVKMESSKQ HFFHLWNDFA YIEVDGKKYP SSEDGIQVVV IDGNQGRVVS HTSFRNSILQ GIPWQLFNYV ATIPDNSIVL MASKGRYVSR GPWTRVLEKL GADRGLKLKE QMAFVGFKGS FRPIWVTLDT EDHKAKIFQV VPIPVVKKKK L //